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The combined thesis submitted for award of the Master of Research in Molecular and 
Cellular Biology consists of two projects.  
The first project with the title “towards a prophylactic Epstein Barr Virus (EBV) vaccine 
to prevent EBV-associated malignancies and infectious mononucleosis” aim was to 
investigate T cell responses in healthy EBV-seropositive donors to two EBV structural 
proteins MCP, encoded by BcLF1, and LTP, encoded by BPLF1. The results of first 
project showed that EBV proteins MCP and LTP are a good vaccine candidates.  
The second project with the title “analysing the transcriptional response to histone 
deacetylase inhibitors treatment in normal and cancer cell lines” aim was to analyse 
the transcriptional response to histone deacetylase inhibitor valproic acid (VPA) 
treatment in normal and cancer cell lines. The results of second project showed that 
VPA is not as toxic to normal cells as other chemotherapeutic agents and is a promising 
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Epstein Barr virus (EBV) is one of the eight human herpesviruses that infects >90% of 
the population. Most people are infected as infants without any symptoms however, 
when people get EBV later in life, 70% of people develop infectious mononucleosis 
(IM). EBV is also associated with several malignancies and in 2008 there were 
approximately 200,000 new cases of EBV-associated cancers worldwide.  
The first generation of EBV vaccines targeted the glycoprotein gp350. While the 
vaccines bolstered immunity, preventing the IM symptoms, people still became EBV-
seropositive. A second generation of vaccines will now target EBV structural proteins. 
As the MCP, encoded by BcLF1, and LTP, encoded by BPLF1, are large and abundant 
structural proteins expressed very early on in infection, they are potential vaccine 
candidates.  
The combined results from three prediction algorithms were used to identify peptide 
sequences from MCP and LTP containing an HLA-A*02 or HLA-B*07 T cell epitope and 
IFN-y responses from nine EBV-seropositive donors were examined.  
Ex-vivo IFN-y responses were small whereas, in-vitro responses expanded. Responses 
were seen from either the CD4+ or CD8+ T cell pool dependent on peptide pool and 
donor. HLA-C*06 restricted CD8+ T cell clones were established from one 
representative donor. CD4+ T cell clones from one representative donors have shown 
recognition of lytic LCLs being of great importance in controlling the EBV infection. The 
EBV structural proteins MCP and LTP are frequent targets of T cells in healthy 
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BCA Bicinchoninic acid 
BSA Bovine Serum Albumin 
CD  Cluster of differentiation 
dH20 Distilled water 
EBV Epstein-Barr virus 
EDTA Ethylene-diamine-tetra-acetic acid 
ELISA Enzyme-linked immunosorbent assay 
ELISPOT Enzyme-linked immunosorbent spot 
EtBr Ethidium bromide 




LB  Luria-Bertain media 
LSM Lymphocyte Separation Media 
MACS  Magnetic-Activated Cell Separation buffer 
MLA Monkey Leukocyte Antigen 
PBMCs Peripheral Blood Mononuclear Cells 
PBS Phosphate-Buffered Saline 
PCR Polymerase Chain Reaction 
RPMI Roswell Park Memorial Institute media 
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Throughout evolution, viruses have acquired various characteristics to infect and 
survive within their hosts. To protect against infection, or to counteract disease 
following virus acquisition, host immunity developed. The human immune system 
consists of relatively simple defences, such as the skin, and stomach acid, and more 
complex defences, including specialised cells that destroy pathogens. Despite these 
defences, humans and other animals can become infected with viruses. Some viruses 
are able to evade immune-surveillance and persist asymptomatically after primary 
infection in a state of dormancy, also known as latency. This is a common 
characteristic of one family of viruses, the human herpesviruses. Herpesviruses cause a 
wide range of diseases including certain malignancies. The two herpesviruses most 
strongly associated with cancer, referred to as tumour-associated viruses or 
oncoviruses, are Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus 
(KSHV) (Butt and Miggin, 2012, Schiller and Lowy, 2010). In 2008, there were 12.7 
million of new cases of cancer worldwide (Jemal et al., 2011) and it is estimated that 
approximately 2 million of these cases were caused by infection. Indeed, 10% of all 
cancers are associated by EBV infection alone (de Martel et al., 2012, Cohen et al., 
2011). Preventing infection with oncoviruses is therefore of great importance, and 
following the success of successful vaccines targeting tumour viruses in the past (e.g., 
Hepatitis B Virus and Human Papilloma Virus) there is significant interest in developing 
a prophylactic EBV-vaccine. This project examined whether EBV structural proteins, 
that are potentially good vaccine targets due to their size and abundance on EBV-
infected cells, elicit frequent immune responses in healthy individuals.  The results of 
this project provide new insight into potential EBV-vaccine candidates.          
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1.2. Immune system  
1.2.1. Innate immunity 
 
The human body is protected against pathogens by several mechanisms. First, the skin 
acts as a physical barrier and deters microbes in several ways, such as having an acidic 
pH (pH 5.5), having a high salt content, regularly shedding cells, and harbouring 
antimicrobial peptides (Percival et al., 2012). Epithelial surfaces in the gut and lungs 
also have protective functions. The gastric acid (hydrochloric acid; HCl) in the stomach 
is of very low pH (approximately 1.7 up to 5.0 during digestion) and inactivates or kills 
pathogens directly (Birk et al., 2012). These mechanical/chemical barriers aim to 
prevent pathogens from entering the body, however, if this first line of protection fails, 
then other secondary mechanisms exist.  
Pathogens can be recognised by cells of innate immune system that protect the human 
body in the first few days of infection. These cells include phagocytic tissue residing 
cells such as macrophages and dendritic cells, and mobile cells such as neutrophils, 
eosinophils and monocytes. Invading pathogens are recognised by pattern-recognition 
receptors (PRRs) on phagocytes (e.g., macrophages). For example, toll-like receptors 
(TLRs) are capable of detecting bacteria and viruses in extracellular spaces as well as in 
the intracellular compartments of the cell. Once the pathogen has been recognised by 
tissue residing macrophages, these cells secrete chemokines. As a result, neutrophils 
migrate to the site of infection and secret cytokines, such as interleukin-1 (IL-1), 
interleukin-12 (IL-12), interleukin-6 (IL-6), interferon-α (IFN-α), interferon-β (IFN-β), 
tumour necrosis factor-α (TNF-α) etc. Cytokines are soluble signalling molecules that 
attract inflammatory cells of both the innate and adaptive immune system (Zepp, 
2010, Moser and Leo, 2010, Alberts et al., 2007, Janeway et al., 1999). Some 
pathogens (e.g., bacteria) can be cleared by the innate immune system, however in the 
case of virus infection, it is necessary to employ the adaptive arm of the immune 
system. 
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1.2.2. Adaptive immunity 
 
There are several distinct properties that are characteristic of the adaptive immune 
system especially when referring to the T cells. First, cells of the adaptive immune 
system can recognise antigens as “self-antigens” or “non-self antigens”. Non-self 
antigens represent peptides derived from invading pathogens, or other foreign 
material. Immune cells with autoreactive receptors recognising “self-antigens” are 
eliminated by negative selection in the thymus. Second, the adaptive immune system 
is able to detect intracellular pathogens, such as viruses. The cells of the adaptive 
immune system survey molecules expressed on the surface of body cells, and will 
recognise any foreign antigen that is presented. Third, after infection has been 
resolved, the adaptive immune system establishes a state of “immunological 
memory”. Thus, if re-infection occurs with the same pathogen, a much faster and more 
vigorous immune response takes place in an attempt to eliminate re-infection (Moser 
and Leo, 2010, Zepp, 2010).  
 
The effector cells of the adaptive immune system are specialised haematopoietic cells 
(lymphocytes) of which there are several sub-types. Lymphocytes are derived from 
lymphoid progenitor cells and differentiate into B lymphocytes (B cells), T lymphocytes 
(T cells) and natural killer cells (NK). Upon activation naïve B cells differentiate into 
plasma cells which secrete antibodies (molecules that can kill or identify pathogens) 
and memory B cells which ensure a rapid immune response upon a second exposure to 
the same pathogen. Naïve T cells upon activation differentiate into cytotoxic T cells 
that destroy infected cells, and helper T cells that stimulate other cells such as B cells, 
macrophages etc. There are two subsets of T cells distinguished by their cell surface 
molecules (i.e. cluster of differentiation; CD). Cytotoxic T cells express CD8 and helper 
T cells express CD4 surface molecules (Moser and Leo, 2010, Janeway et al., 1999, 
Wang et al., 2013a).           
 
The adaptive immune system is composed of primary (e.g., thymus and bone marrow) 
and secondary (e.g., lymph nodes and spleen) lymphoid organs. In bone marrow B cells 
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and T cells are generated but only B cells mature in bone marrow whereas, T cells 
migrate and mature in thymus. Mature B and T cells migrate through blood stream 
into secondary lymphoid organs (Moser and Leo, 2010).  
 
Viruses replicate inside cells, and use host cellular machinery to produce virus-derived 
proteins. Infected cells express (and sometimes release) these proteins or peptides 
(referred to as antigens) that can be recognised by lymphocytes. B cells have B cell 
antigen receptor (BCR) that is capable of recognising soluble antigen. When activated, 
B cells secrete antibodies, also referred to as immunoglobulins, which bind to antigen 
in blood or lymph and facilitate its destruction by phagocytes in a process known as 
opsonisation. Antibodies bound to cell surface antigens can activate a series of 
proteins found in blood (the complement system; part of innate immunity) inducing 
cell lysis and destruction of the target. Antibody binding can also sometimes directly 
neutralize pathogen, preventing further infection (Moser and Leo, 2010).  There are 
several classes of antibodies, also referred to as immunoglobulins. IgM antibodies are 
secreted during primary responses and IgG are secreted later on in infection. Other 
immunoglobulin sub-classes exist, including IgA that is found in secretions on muscosal 
membranes, IgE that is associated with allergic responses and IgD which is co-
expressed with IgM on surface of mature B cells and is suggested to be a 
transmembrane antigen receptor (Chen and Cerutti, 2011, Moser and Leo, 2010). As 
explained later, the goal of vaccination is often to increase the number of neutralising 
antibodies preventing viruses to infect the cell.  
 
T cells are able to identify virus-derived peptides expressed on infected cells, or 
peptides characteristic of changes within self cells, such as malignant transformation. T 
cells have a T cell receptor (TCR) that is unable to recognise soluble antigen. Pathogen 
derived proteins in infected cells are degraded into small peptides and presented on a 
cell surface by transmembrane presenting molecules known as human leukocyte 
antigen (HLA), or major histocompatibility complexes (MHC) (Moser and Leo, 2010, 
Patronov and Doytchinova, 2013). In the cytosol, proteins are degraded into small, 9 – 
11 amino acid long peptides, and presented on the cell surface to CD8+ T cells by MHC 
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class I molecules in an MHC class I/peptide complex. Professional antigen presenting 
cells (i.e., dendritic cells; DCs) present longer peptides usually 15 – 24 amino acids long 
(Zavala-Ruiz et al., 2004) by MHC class II molecules in MHC class II/peptide complexes 
recognised by CD4+ T cells. Upon recognition of antigenic peptides, CD8+ T cells 
become activated and can directly kill target cells through several mechanisms. Upon 
binding with a target cell, T cells secrete perforin, a pore-forming protein that punches 
holes in the membranes of the infected cells. The T cell then releases proteases (e.g., 
granzyme-A) that can enter the cell though the pores, and by degradation of 
intracellular proteins, trigger apoptosis causing rapid death of an infected cell (Moser 
and Leo, 2010, Flesch et al., 2012).  CD8+ T cells are also able to induce cell death 
through other pathways, including interaction between the Fas-ligand on T cells with 
the Fas-receptor on target cells (Moser and Leo, 2010, Patronov and Doytchinova, 
2013, van Lier et al., 2003). Harnessing both the innate and adaptive immune system 
to fight against disease causing pathogens through vaccination is therefore of a great 
importance.     
 
1.3. Vaccination against viruses 
 
In the past century vaccination has saved millions of lives by reducing the incidence of 
many infectious diseases including diphtheria, mumps, and measles (Zepp, 2010, 
Rappuoli et al., 2011). Due to advances in scientific understanding, vaccination is not 
only used to prevent infectious disease, but is also used to provide therapy for other 
diseases such as cancer (Rappuoli et al., 2011, Zepp, 2010).  
 
All vaccines present an antigen to the immune system and initiate an immune 
response. Prophylactic or preventative vaccines are administered prior to pathogen 
exposure and aim to prevent infection and therefore disease. Some vaccines can be 
administered after exposure to the pathogen. These so-called post-exposure-
prophylactic vaccines aim to counteract the infection before it takes hold, and 
therefore limit disease (Patronov and Doytchinova, 2013, Wu et al., 2010). Therapeutic 
vaccines are used for the treatment of malignancies by boosting immune responses 
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and the aim is to destroy tumour cells expressing tumour-associated antigens (TAA) 
(Dougan and Dranoff, 2012, Wang et al., 2013b).     
 
There are several vaccine formulations. Inactivated vaccines contain virus particles that 
have been altered by high temperature or chemicals, and thus the virus loses the 
ability to replicate. The vaccine however can still provoke large immune responses. 
Live attenuated vaccines contain virus particles with low levels of virulence. These 
viruses are selected by passaging the virus in multiple rounds of cell culture, or 
growing it in cells from a different species, so that the ability of the virus to infect 
human cells is reduced. The virus is however able to replicate, and therefore provides 
a source of antigen until it is eventually eliminated by the immune system. Subunit 
vaccines provoke immune responses without introducing infectious virus. One 
example of a subunit vaccine is the hepatitis B vaccine that contains the surface 
antigen HBsAg that is normally expressed by infected cells (Shouval, 2003, Schiller and 
Lowy, 2010). Virus-like particles (VLP) vaccines contain viral proteins without viral 
nucleic acid, thus are non-pathogenic as the virus cannot replicate. The most recent 
advance in vaccinology exploits DNA vaccines containing genetically engineered virus 
DNA that is incorporated into body cells. Thus, virus proteins are produced by the cell 
and expressed on the cell surface. A gene encoding a previously identified 
immunodominant B cell and/or T cell antigen is usually chosen as antigen (Patronov 
and Doytchinova, 2013). For example, the DNA vaccine described by Hui et al., 2013 
consisted of Modified Vaccinia Ankara Virus vector with an insert of EBV viral genes 
encoding two EBV proteins known to be expressed by EBV-associated tumour cells.         
 
Vaccinations are often administered intradermally, intramuscularly or subcutaneously 
(Combadiere and Liard, 2011). Other delivery methods are used (e.g., oral vaccination 
with polio) and other vaccine routes are currently being developed, including 
intranasal vaccination (Rose et al., 2012), aerosol vaccination (Giudice and Campbell, 
2006), transcutaneous or transdermal vaccination (Giudice and Campbell, 2006, 
Combadiere and Liard, 2011), rectal and vaginal vaccination (Neutra and Kozlowski, 
2006, Yu and Vajdy, 2010).    
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Herpesviruses are enveloped viruses containing a double-stranded DNA genome (Wu 
et al., 2010, Meyding-Lamadé and Strank, 2012, Gilden et al., 2007). The family 
Herpesviridae consists of three subfamilies Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae. Eight herpes viruses have been formally classified: herpes 
simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella zoster virus 
(VZV or HSV-3), Epstein-Barr virus (EBV or HHV-4), cytomegalovirus (CMV or HHV-5), 
human herpesvirus type 6 (HHV-6), human herpesvirus type 7 (HHV-7) and Kaposi’s 
Sarcoma-associated herpesvirus (KSHV or HHV-8) (Table 1) (Davison, 2011, Adams and 
Carstens, 2012, Taylor and Blackbourn, 2011, Meyding-Lamadé and Strank, 2012, 
Gilden et al., 2007). Recently, it has been suggested that HHV-6 should be split into 
two distinct viruses – type 6A and type 6B (Davison, 2011) (see table 1). 
 
Herpesviruses typically exhibit very few hallmarks of infection. Primary infection 
usually occurs in childhood and often passes with no symptoms (Gilden et al., 2007). 
Herpes viruses have two distinct life cycles or phases. In the lytic phase, the virus is 
actively replicating causing lysis of infected cells and infecting other cells or organisms. 
In the case of saliva transmitted herpesviruses (e.g. EBV) infectious virus particles are 
released into saliva enabling infection of another naïve host upon close contact. When 
the infection is brought under control, the virus shifts into a latent phase, 
characterised by few or no symptoms of disease. During this latent phase, the virus 
successfully evades the immune system using a variety of strategies (Wu et al., 2010).  
 
There are several different mechanisms by which herpesviruses evade immune 
recognition such as restriction of gene expression, down regulating MHC class I 
expression and production of cytokines (e.g. interleukin-10 – an anti-inflammatory 
cytokine) (Banks and Rouse, 1992). Herpesviruses have the ability to re-activate after 
latency and realise viral particles causing lysis of infected cells and infection of non-
infected cells. This phase is called lytic replication (Wu et al., 2010, Meyding-Lamadé 
and Strank, 2012, Gilden et al., 2007, Davison, 2011). The two phases - latency and lytic 
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replication are continuous processes, and herpesviruses therefore can infect their 
hosts persistently for life (Wu et al., 2010). 
 
Although herpesviruses exist within hosts for a lifetime, the infection is usually 
asymptomatic and the majority of infected people will never develop a virus-
associated disease. However, some herpes viruses can cause life-threatening diseases 
in immune-compromised individuals such as HIV-positive individuals, transplant 
patients on immunosuppressive therapy and individuals with x-linked 
lymphoproliferative disease (Wu et al., 2010, Hislop et al., 2007, Kutok and Wang, 
2006). However, some healthy individuals can develop herpes viruses associated 
malignancies as two herpesviruses (EBV and KSHV) are already classified as agents 
carcinogenic to humans (Taylor and Blackbourn, 2011).  
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Table 1: Human Herpesviruses (HHV) characteristics 




HHV-1 Herpes simplex virus-1 
(HSV-1)  
Sensory nerve ganglia Close contact (sexually 
transmitted disease) 
Painful skin or mucosal 
lesions 
Oral lesions (cold 
sores) 
HHV-2 Herpes simplex virus-2 
(HSV-2)  
Sensory nerve ganglia Close contact (sexually 
transmitted disease) 
Genital lesions Genital lesions 
HHV-3 Varicella zoster virus (VZV) Sensory nerve ganglia (cranial 
nerve) 
Respiratory and close contact  Varicella (chickenpox) Herpes zoster 
(shingles) 
HHV-4 Epstein-Barr virus (EBV) B cells, endothelial and 
epithelial cells  
Close contact (saliva), 






HHV-5 Cytomegalovirus (CMV) Bone marrow progenitor cells 




CMV disease, CMV 
retinitis, CMV - 
gastroenteritis 
HHV-6 Roseolovirus, Herpes 
lymphotropic virus 
Monocytes and macrophages  Close contact, saliva Roseola (sixth disease) Unknown 
HHV-7 Human herpesvirus-7 Monocytes, lymphocytes and 
salivary glands 











Information summarised from (Davison, 2011, Gilden et al., 2007, Hislop et al., 2007, Schiffer and Corey, 2013, Taylor and Blackbourn, 
2011, Viner et al., 2012, Wu et al., 2010).
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1.5. Epstein-Barr virus (EBV) 
 
EBV is a herpesvirus of the gamma subfamily and is also known as human herpes virus-
4 (HHV-4) (Kutok and Wang, 2006, Wu et al., 2010). There are two major types of EBV, 
type A or EBV-1 with highest prevalence in the West and type B or EBV-2 with highest 
prevalence in Africa. Although other data suggests that both types coexist equally in 
the same human population (Straus et al., 1993) and individuals can be infected with 
multiple strains and/or types. However, it is not established whether reinfection with 
multiple strains occurs over time or if individuals acquire multiple strains at primary 
infection (Sitki-Green et al., 2003, Tierney et al., 2006). EBV is transmitted by saliva and 
has a high infectious rate as over 90% of human population is infected. Infection 
usually occurs in early childhood and passes asymptomatically. If primary infection 
occurs later in life individuals can develop infectious mononucleosis (IM) with 
symptoms such as sore throat, fatigue, fever, pharyngitis etc. (Cohen et al., 2011, 
Cohen, 2000, Kutok and Wang, 2006, Straus et al., 1993, Luzuriaga and Sullivan, 2010). 
The EBV genome is linear double-stranded DNA with approximately 184,000 base pairs 
(Straus et al., 1993, Kutok and Wang, 2006, Luzuriaga and Sullivan, 2010) encoding 
approximately 100 viral proteins (Straus et al., 1993, Cohen, 2000). The EBV genome is 
enveloped within capsid and viral tegument alongside viral envelope (see figure 2) 
(Kutok and Wang, 2006, Cohen, 2000). Capsid and viral tegument contain many 
proteins such as glycoprotein 350 (gp350) which is the target of neutralising 
antibodies. EBV is associated with several conditions.  
 
1.5.1. Infectious mononucleosis (IM) 
 
Symptoms of IM often occur after an incubation period of 30 to 50 days after the first 
exposure to EBV (Luzuriaga and Sullivan, 2010). IM is a sign of primary EBV infection 
(Luzuriaga and Sullivan, 2010) and usually affects adolescents or young adults in their 
first three decades of life (Cohen, 2000, Luzuriaga and Sullivan, 2010). Diagnosis is 
based on triade of clinical symptoms such as fever, pharyngitiy and adenopathy. 
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Laboratory findings usually show atypical lymphocytes (Luzuriaga and Sullivan, 2010, 
Straus et al., 1993, Kutok and Wang, 2006, Cohen, 2000). Symptoms can persist for few 
weeks however fatigue can persist for 6 months or even longer. The majority of 
patients entirely recuperate after 2-3 months (Luzuriaga and Sullivan, 2010). After 
symptoms have resolved lytic infection proteins can be found in blood even a year 
after IM and proteins associated with latent infection persist for life time with 
recurrent shifts to lytic infection without clinical symptoms (Luzuriaga and Sullivan, 
2010). 
 
1.5.2. EBV-associated diseases 
 
EBV is associated with several other diseases besides infectious mononucleosis. EBV 
was the first virus linked to human cancer. The link between EBV and human cancer 
was discovered with identification of EBV virion in cells of Burkitt lymphoma (Michelow 
et al., 2012). The diseases associated with EBV are Hodgkin lymphomas, non-Hodgkin 
lymphomas, posttransplant lymphoproliferative disorder (PTLD), pyothorax-associated 
lymphomas, nasopraryngeal carcinomas, smooth muscle tumours, follicular dendritic 
cell tumours, Burkitt lymphomas, and gastric carcinomas (Michelow et al., 2012, Straus 
et al., 1993, Long et al., 2011, Taylor and Blackbourn, 2011, Kutok and Wang, 2006). In 
2008 there was approximately 200,000 new cases (10%) of EBV associated 
malignancies worldwide of which there was approximately, 13,200 new cases of 
Hodgkin lymphomas, 6,300 new cases of Burkitt lymphomas in Africa and 
approximately 60,000 new cases of nasopharyngeal carcinomas attributed to EBV (de 
Martel et al., 2012). Gastric carcinoma is most common EBV-associated malignancy as 
there are 1 million new cases per year worldwide and estimated 90,000 cases are EBV-
associated (Cohen et al., 2011). EBV infection has also been associated with 
autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and 
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1.6. Mechanisms of EBV infection and virus protein expression 
 
The internalization of EBV viral capsid or nucleoprotein core into the host cell is the 
most important step in viral infection (Shaw et al., 2010). Upon transmission to a naïve 
host, the virus replicates in cells of oropharynx (probably epithelial cells) (Hislop et al., 
2007). After infection of a cell (usually by a single virion), EBV DNA changes from being 
linear to circular episomal DNA (Kutok and Wang, 2006) although, such circularisation 
is specific to memory B cells, and therefore does not happen in normal infection of 
epithelial cells. Infection of B cells is activated by attachment of glycoprotein 350/220 
(gp350/220) to B cell surface molecule CD21. After attachment, the virus is internalised 
and engulfed in cytoplasmic vesicle. The glycoprotein 42 (gp42) binds to the HLA class 
II receptor. (Shaw et al., 2010, Kutok and Wang, 2006). Another route of infection can 
occur by attachment of gp350/220 to B cell surface molecule CD35 also causing 
persistent infection as in infection through CD21 (Ogembo et al., 2013). The EBV genes 
BZLF1 and BRLF1 trigger the shift from latent to lytic cycle enabling virus shedding and 
lifelong persisting infection in the host (Kutok and Wang, 2006, Hislop et al., 2007). 
After primary infection, lytic cycle proteins are expressed and can be divided into three 
groups: immediate early (IE) proteins, early (E) proteins and late (L) proteins. After lytic 
cycle latency occurs and latent peptides are expressed (see figure 1) (Hislop et al., 
2007).     
 
As already described in section 1.5 EBV consists of envelope, tegument, capsid and 
viral DNA. The EBV genes probably encode six capsid proteins (Henson et al., 2009), 
five envelope proteins and ten tegument proteins. Among the envelope glycoproteins 
such as gp42, gB, gL, gH, is the glycoprotein gp350 the most dominant and the largest 
EBV envelope glycoprotein with 350 kDa (Johannsen et al., 2004). Therefore gp350 has 
received attention as a target for vaccination (Cohen et al., 2013). 
 
The research presented in this thesis is focused on two EBV proteins that are already 
present on the incoming virion. The major capsid protein (MCP), encoded by the gene 
BcLF1, (Henson et al., 2009) and the large tegument protein (LTP), encoded by the 
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gene BPLF1 (Schmaus et al., 2004, Whitehurst et al., 2012) (see figure 2). The EBV 
capsid proteins are encoded by six genes, one being BcLF1, which by mass, is the 
largest of all six capsid proteins (155 kDa) (Henson et al., 2009, Johannsen et al., 2004). 
In the normal lytic cycle, the BcLF1 gene is expressed in the late phase (Adhikary et al., 
2007). Data from Prang et al., 1997 shows that the BcLF1 gene can be detected at 
primary infection when IM symptoms occur but cannot be detected in healthy EBV-
seropositive people, who are likely to be in a state of latency. Thus, BcLF1 is an 
attractive vaccine candidate due its existence on the incoming virion, as well as 
relatively early expression in the lytic cycle. The second protein examined in this thesis 
is the LTP encoded by BPLF1. This is one of the ten tegument proteins, and is by mass, 
the largest of all EBV tegument proteins at 350 kDa (Johannsen et al., 2004). BPLF1 is 
also expressed in the late phase of the lytic cycle, but is also present on the incoming 
virion, making it another potentially attractive vaccine target (Schmaus et al., 2004, 
Whitehurst et al., 2012). BPLF1 specific antibodies can be detected at primary infection 
with EBV, in people with EBV reactivation, in EBV-positive tumours and in more than 
half of EBV-seropositive healthy people (Schmaus et al., 2004). It has also been 
suggested that inhibition of the BPLF1 can cause inhibit EBV replication (Gastaldello et 
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Figure 1: Diagram of EBV proteins in EBV-seropositive healthy people. Proteins are presented as 
immediate early (IE) proteins, early (E) proteins and late (L) proteins of the lytic cycle and the proteins of 
latent cycle with relative immunodominance for CD8+ and CD4+ T cell responses. Dotted arrows denote 
CD4+ T cell responses where their relative immunodominance is not yet determined. Proteins denoted 
as n.t. were not tested. The two asterisks (*) denote two genes (BcLF1 and BPLF1) encoding proteins to 
which responses were investigated in this project. Figure adapted from (Hislop et al., 2007).  
 
 
Figure 2: The EBV structure. EBV consists of an envelope, with the most dominant glycoprotein gp350, a 
tegument, a capsid and DNA. The major capsid protein (MCP), encoded by BcLF1, and large tegument 
protein (LTP), encoded by BPLF1, are denoted with protein size and mass. Figure adapted from (Draborg 
et al., 2012).  
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1.7. EBV vaccines and immunotherapies 
 
The majority of human population is infected with EBV but most people never develop 
EBV-associated diseases. However, there are also certain risk groups of people who 
can develop EBV-associated diseases, such as transplant recipients, HIV positive 
individuals, and individuals living in parts of the world with high incidence of Burkitt 
lymphoma and nasopharyngeal carcinoma (Cohen, 2000, Wu et al., 2010, Cohen et al., 
2013). Two forms of EBV vaccines are being developed. Prophylactic vaccines aim to 
prevent EBV infection, and might prevent IM and reduce the incidence of cancers 
associated with EBV (Long et al., 2011, Schiller and Lowy, 2010, Münz and Moormann, 
2008).  Therapeutic EBV vaccines aim to enhance natural immunity and reduce the risk 
of EBV-associated malignancies. These vaccines would be administrated after primary 
EBV infection (Wu et al., 2010, Cohen et al., 2011). Therapeutic EBV vaccines can also 
be used as immunotherapies for treatment of EBV-associated malignancies as clinical 
trial data has shown a resolution of lesions in nasopharyngeal carcinoma (NPC) and 
Hodgkin lymphoma patients (HL) in patients administered with an EBV vaccine (Cohen 
et al., 2011). In NPC patients, a phase II clinical trial was conducted to assess the 
infusion of EBV-specific cytotoxic T lymphocytes (EBV-CTL) targeting the latent 
membrane protein 2 (LMP2) because LPM2 is a protein expressed on majority of NPC 
tumours. The results showed a two-fold expansion of LMP2 specific T cells two weeks 
after infusion returning to normal levels six weeks later. Expansion and responses were 
measured with enzyme-linked immunosorbent spot (ELISPOT) assay (Louis et al., 
2010).  
 
1.8. Human EBV vaccine trials 
 
Several EBV vaccine trials have been conducted. The majority of vaccines tested 
focused on stimulating neutralising antibodies to glycoprotein 350 (gp 350) – a protein 
important for B cell infection with EBV. In one phase II clinical trial, 181 EBV-
seronegative young adults aged 16 to 25 years were given a recombinant gp350 
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vaccine. The responses to vaccine were assessed by measuring anti-gp350 antibodies 
by gp350 enzyme-linked immunosorbent assay (ELISA). The vaccine was protective 
against IM in 78% of people but did prevent EBV infection. Interestingly, 8/9 
individuals in the non-vaccinated control group developed IM on primary infection 
(Sokal et al., 2007).  
 
Another trial which was the first vaccine trial in humans using recombinant vaccinia 
virus also exploiting gp350 was conducted on nine EBV-seronegative infants who were 
immunized with vaccinia virus expressing gp350/220. The vaccine protected infants 
from infection for the duration of the study (16 months) as 6/9 vaccinated infants 
remained EBV-seronegative, compared to 10/10 in the non-vaccinated control group 
(Gu et al., 1995). After the completion of the trial EBV-seronegative infants were not 
followed up, thus the, long term effectiveness of the vaccine is not known. However, 
the results of this trial suggest that live viral vectors can offer better protection against 
EBV, compared to sub-unit vaccines, potentially because both humoral and cellular 
immunity are targeted (Cohen et al., 2011).  
 
A recent phase I trial of a therapeutic vaccine examined MVA expressing tumour 
antigens EBNA1 and LMP2 that are expressed on most NPC tumours. The trial was 
conducted on patients in NPC remission to determine the safe and immunogenic dose. 
The data showed a clear increase in IFN-y production by EBV specific T cells measured 
by ELISPOT assay in comparison to control antigens not included in the vaccine 
(EBNA3A and an influenza antigen) showing no increase in response after vaccination. 
The trial showed that this particular vaccine is safe and immunogenic and further trials 
should be conducted understand the clinical effects (Hui et al., 2013).  
 
A phase I trial using single synthetic HLA-B*0801 restricted CD8+ T cell epitope was 
conducted on fourteen EBV-seronegative individuals from age of 18 to 50. The results 
showed that the vaccine was well tolerated and expanded the numbers of EBV-specific 
T cells within two weeks of vaccination. These EBV-specific T cells produced IFN-ƴ in 
response to peptide and destroyed targets. Five out of ten vaccinated volunteers 
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became EBV-seropositive, and two out of four volunteers in control group became 
EBV-seropositive. Thus, while the efficacy of a single epitope T cell vaccine remain 
unclear, this data shows that a strong T cell response can be elicited by vaccination 
(Elliott et al., 2008).             
 
1.9. The ideal EBV vaccine  
 
The ideal EBV vaccine would prevent primary EBV infection and therefore prevent the 
development of EBV-associated malignancies. Potential vaccine targets are large 
proteins that are abundantly expressed very early on in primary infection allowing the 
immune system to recognise infection and respond by destroying the newly infected 
cells. Potential vaccines might combine novel targets with glycoprotein gp350, 
considering this is the target of neutralising antibodies. Despite the efficacy of live and 
live attenuated vaccines this is probably not an option for vaccinating against EBV, 
considering that EBV is an oncovirus that establish lifelong latent infection, and might 
increase the risk of cancer. 
 
1.10. Summary, overview and aims of this thesis. 
 
Part one of this thesis is split into two sections, cell biology and molecular biology. The 
aim of cell biology part of the project was to examine T cell responses to two EBV 
structural proteins MCP (BcLF1) and LTP (BPLF1) which have not been extensively 
investigated before in EBV-seropositive healthy individuals 
 
The data obtained and presented in this thesis shows that individuals exhibit frequent 
responses, derived from both the CD8+ and CD4+ T cell pool, to EBV structural 
proteins.  The major aims of this thesis were to: 
1. Examine whether healthy individuals exhibit T cell responses to the EBV structural 
proteins BcLF1 (MCP) and BPLF1 (LTP).  
2. Examine whether these responses can be expanded in vitro. 
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3. Examine whether these responses were from the CD4+ or CD8+ T cell pool. 
4. Establish T cell clones specific for the MCP and LT from a representative donor  
5. To determine the HLA-type of these clones 
6. To begin experiments to show that the MCP and LTP might be good vaccine 
candidates 
 
The aim of molecular biology part of the project was to produce a tool to so that T cell 
responses to whole protein antigens encoded by BcLF1 and BPLF1 genes could be 
established in individuals, avoiding complications over HLA-type. The BcLF1 gene had 
already been inserted into an appropriate vector before this project started. 
Therefore, to achieve our aim the BPLF1 had to be inserted into a vector. In order to 
examine the CD4+ T cell responses invariant chain had to be inserted into the vector.  
Therefore, the aims were: 
1. To amplify BPLF1 protein gene by PCR. 
2. To insert invariant chain into pENTR1A vector. 
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Reagent in text Formulation 
10% RPMI RPMI (Sigma Life sciences, USA), 10% main batch FCS (PAA 
laboratories GmbH, Austria), 1% streptomycin and penicillin 
(Invitrogen) 
10% B cell RPMI RPMI, 10% main batch B cell FCS (Biosera, South America 
Origin), 1% streptomycin and penicillin 
1% RPMI HUS   RPMI, 1% Human Serum (TCS Biosciences Ltd, UK), 1% 
streptomycin and penicillin  
50x TAE buffer For 500 ml: 
121 g Tris base in 250 ml dH2O, 28,6 ml acetic acid, 50 ml 0,5 
M EDTA pH 8,0 and dH2O to 500 ml 
 
1x TAE buffer 50x TAE, 1960 ml dH2O and 40 µl EtBr (10 mg/ml) 
 
IL-7 media RPMI, 10% B cell FCS, 1% streptomycin and penicillin, 5 µl IL-
7 (Peprotech) 
 
IL-2 media RPMI, 10% B cell FCS), 1% streptomycin and penicillin, IL-2 
50 IU/ml (Peprotech) 
Lymphocyte separation 
medium 
PAA laboratories GmbH, Austria 
MACS buffer Distilled water, PBS (Oxoid Ltd, UK), BSA, EDTA 
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Other reagents Source 
IFN-γ ELISPOT  
 
Mabtech, Sweden 
Anti-CD4 beads  
 
Invitrogen Dynal AS, Norway 
DNA Molecular Weight 
Marker X  
 
Roche applied science 
Expand Long Template 
PCR System 
 




New England BioLabs, UK 
QIAprep spin miniprep 
Kit 
 
QIAGEN, Sussex, UK 
QIAquick Gel Extraction 
Kit 
 











Bajt T. Towards a prophylactic Epstein Barr Virus (EBV) vaccine to prevent EBV-associated malignancies 
and infectious mononucleosis. MRes thesis, University of Birmingham, 2013. 





2.3. Cell Biology Techniques 
 
2.3.1. T cell epitope prediction 
 
Amino acid sequences of the EBV major capsid protein (MCP) encoded by BcLF1 and 
the large tegument protein (LTP) encoded by BPLF1 were obtained from the National 
Center for Biotechnology Information (NCBI) database. HLA-A*02 or HLA-B*07 
restricted CD8+ T cell epitopes (9-mers) were predicted using three prediction 
programmes available online Syfpeithi (Rammensee et al., 1999), BIMAS (Parker et al., 
1994) and the Immune Epitope Database (IEDB) (Salimi et al., 2012). The top 2% of 
epitopes predicted by Syfpeithi were compared with the top 20 epitopes predicted by 
BIMAS and the top 20 epitopes predicted by IEDB. The 9-mer epitopes were extended 
into 20-mers to allow for potential recognition by CD4+ T cells. For BcLF1 there were 
sixteen peptides predicted and for BPLF1 there were twenty-five peptides predicted 
and synthesised by AltaBiosciences (Birmingham, UK) (table 2).  
 
2.3.2. Bicinchoninic (BCA) assay 
 
Protein concentration of synthesised peptides was determined by the bicinchoninic 
assay (Pierce Biotechnology, USA) (Smith et al., 1985). Briefly, the BCA assay combines 
the reduction of Cu2+ to Cu+1 by peptide (the biuret reaction) with the colorimetric 
detection of the cuprous cation (Cu+1) using bicinchoninic acid. Standards (125µg/ml 
up to 2000 µg/ml), samples and a blank (DMSO only) were added to a 96 well plate. 
BCA working reagent was added, wells mixed, and the plate was incubated at 37°C for 
30 min. Absorbance was measured at 560 nm using a micro-plate reader (Bio-rad, 
model 680). 
 
2.3.3. T cell epitope peptide pools 
 
Predicted T cell epitopes (peptides) were organised into peptide pools shown below 
and used in assays at a concentration 2 µg/ml (see table 2). 
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Table 2: T cell epitope peptide pools 
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2.3.4. T cell epitope control peptides 
 
Peptides derived from several EBV proteins, known to elicit a response in donors based 
on previous experiments (data not shown), were used as positive controls at a final 
concentration of 2 µg/ml (see table 3). 
 
 
Table 3: T cell epitope control peptides 




EBNA1 Latent B35.01 HPVGEADYFEY HPV 
EBNA3A Latent B7 RPPIFIRRL RPP 
EBNA3A Latent B8 FLRGRAYGL FLR 
EBNA3C Latent B7 QPRAPIRPI QPR 
LMP2 Latent A2 CLGGLLTMV CLG 
BRLF1 Lytic A2 YVLDHLIVV YVL 
BZLF1 Lytic B35.01 EPLPQGQLTAY EPL 
 
 
2.3.5. Blood sample collection 
 
Blood was collected into lithium heparin vacutainers from nine EBV-seropositive 
healthy donors via venepuncture of a forearm vein. Blood was collected following 
ethical approval given by South Birmingham Research Ethics Committee (reference: 
07/Q2702/24).  
 
2.3.6. Blood sample processing 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood using density 
gradient centrifugation. Blood was diluted 1:1 with plain RPMI and carefully layered 
upon lymphocyte separation media (LSM). Tubes were centrifuged at  for 30 
min at room temperature (no brake). Lymphocytes were harvested from the interface 
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between plasma and LSM. Cells were washed twice in plain RPMI by centrifuging at 
 for 10 min and  for 5 min (low brake) at room temperature. Cells 
were re-suspended in 10% RPMI and counted using a haemocytometer. 
 
2.3.7. Thawing cells 
 
Cells were thawed in a 37°C water bath and slowly re-suspended in 10% RPMI using 
the drip-by-drip method. Cells were washed twice in 10% RPMI at  for 5 min 
(low break). Cells were re-suspended in 10% RPMI and counted using a 
haemocytometer. 
 
2.3.8. Freezing cells 
 
Cells in 10% RPMI were centrifuged at  for 5 min, re-suspended in freezing 
mix, and transferred to a cryovial. Vials were frozen at −1°C/min to −80°C using a 
freezing container (Mr Frosty, Nalgene). Cells were moved to  −196°C within 24 hours. 
Figure 3: Schematic diagram of cell biology experiments time course. After collection and processing of 
blood sample obtaining PBMCs first, “ex-vivo ELISPOT assay” was performed alongside preparation of 
cells for 7 day culture for “7 day ELISPOT assay”. After obtaining the results of both ELISPOT assays 
blood sample from the same donor was taken again to “establish polyclonal T cell lines”. Alongside 
culturing T cells “CD4+ T cell depletion” was performed and the next day “depletion ELISPOT assay”. The 
next day “IFN-ƴ capture and cloning by limiting dilution” was performed from polyclonal T cell lines. 
Potential clones were incubated at 37°C for approximately 3 weeks and identified. Identified potential 
clones were screened using “Elisa assay” and if positive for selected peptide pool clones were expanded 
by “rapid expansion protocol”. After two weeks of incubation at 37°C T cell clones were identified by 
“fluorescence activated cell sorting” and HLA restriction was performed by Elisa assay the next day.      
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2.3.9. Ex-vivo ELISPOT assay 
 
T cell responses to predicted T cell epitopes were assessed using IFN-γ ELISPOT. PVDF-
membrane plates were treated with 70% ethanol in sterile distilled water for 30 sec. 
Treated plates were washed twice with filtered PBS. Plates were coated with anti-
human IFN-γ antibody 1-DIK) at concentration of 7.5 µg/ml. Plates were incubated at 
room temperature for 3 hours. Plates were washed four times with filtered PBS and 
blocked with 10% RPMI. Plates were incubated at room temperature for 1 hour. 
Lymphocytes were added at 250,000 cells/well in duplicate. Predicted and control 
peptides were added at a concentration of 2 µg/ml per well. A negative control (10% 
RPMI media) was included in all assays. Plates were incubated overnight at 37°C. After 
12-16 hours, plates were washed with 0.05% Tween/PBS eight times. The secondary 
antibody (Anti-human IFN-γ 7-B6-1-biotin) was added at concentration of 1µg/ml. 
Plates were incubated for 3 hours at room temperature. Plates were washed with 
0.05% Tween/PBS solution eight times. Third antibody (Streptavidin-Alkaline 
Phosphatase) at ratio of 1:1000 was added and plates incubated for 1 hour and 30 min 
at room temperature. Plates were washed with 0.05% Tween/PBS solution eight times 
and filtered PBS three times. Substrate (TMB) was added and plates left to develop for 
45 min. Colour development was stopped by rinsing plates with tap water. Plates were 
read on ELISPOT reader (Aid ELISPOT Reader). Spots were expressed relative to 1 
million cells. 
 
2.3.10. 7 day (in-vitro) ELISPOT assay 
 
PBMCs were plated out in round bottom 96 well plates containing 10% RPMI in an 
identical format to the ex-vivo ELISPOT assay. Peptides were added to well in duplicate 
at 2 µg/ml. Plates were incubated for 7 days. After 7 days cells were washed four times 
in 10% RPMI by centrifuging at  for 5 min (low break) at room temperature. 
Cells were re-suspended in 10% RPMI and transferred on to PVDF-membrane plates. 
One of the duplicate wells was stimulated with peptide, whereas the parallel well 
served as a negative control to give an indication of background IFN-y. T cell responses 
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to predicted T cell epitopes were assessed using IFN-γ ELISPOT as described above in 
ex-vivo ELISPOT assay section. Plates were read on ELISPOT reader (Aid ELISPOT 
Reader). Spots were expressed relative to 1 million cells. 
 
2.3.11. Establishing polyclonal T cell lines  
 
PBMCs were counted using a haemocytometer. From a starting number of  
cells, one third of cells were pulsed with peptide for for 2 hours at 37°C.  The remaining 
cells were left in media at 37°C. After incubation, peptide-pulsed cells were washed by 
centrifuging at  for 5 min at room temperature and combined with non-
peptide pulsed cells. Cells were re-suspended in media containing IL-7 and plated out 
onto 24 well plates at  cells/well. After two days IL-2 was added at 50 
IU/ml. 
 
2.3.12. CD4+ T cell depletion 
 
By examining results from the ex-vivo and 7 day ELISOT assays, peptide pools 
stimulating a response in donors were defined. To determine which subset of T cells 
responded to predicted T cell epitopes, CD4+ T cell depletion was performed to 
separate CD4+ and CD8+ T cells which we then examined for IFN-y responses. 
Polyclonal T cell lines were established, and after 7 days, cells were washed three 
times with media at  for 5 min at room temperature and counted using a 
haemocytometer. Anti-CD4 beads were washed twice in RPMI and added to cells at 
concentration of 4 beads per CD4+ T cell, assuming that CD4+ T cells represent 2/3 of 
the total cell count. Beads were incubated with cells at 4°C for 30 min. The CD4+ 
fraction was isolated using a magnet (Invitrogen Dynal AS, Norway) and the CD4-
negative fraction was transferred to a new tube. The CD4+ fraction was re-suspended 
in media and transferred into a 24 well plate and left for 4 hours at 37°C to allow beads 
to detach from cells. The CD4+ fraction (minus beads) were collected as the non-
adherent fraction of cells were transferred into new tubes and washed once with 
media at  for 5 min at room temperature. Cells were re-suspended in media, 
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counted and plated out onto PVDF-membrane plates. Cells were assessed by IFN-y 
production by ELISPOT as described in section 2.3.9. 
 
2.3.13. IFN-γ capture prior to cloning by limiting dilution  
 
A polyclonal T cell line was established from a representative donor using the peptide 
pool known to elicit a large IFN-ƴ response. Antigen specific cells from a polyclonal T 
cell line were enriched using an IFN-ƴ secretion and capture kit (Miltenyi Biotec Ltd., 
UK). Polyclonal T cell lines were pulsed with peptides at concentration of 2µg/ml for 3 
hours. Polyclonal T cells were washed in MACS buffer at  for 5 min at 4°C and 
re-suspended in cold media (5% RPMI HS). IFN-γ catch reagent was added and 
incubated for 10 min on ice. Warm media was added and cells were incubated at 37°C 
for 45 min on rotator to allow for IFN-γ secretion. After incubation cells were placed on 
ice for 3 min and then topped up with cold MACS buffer. Cells were centrifuged at 
 for 5 min at 4°C and re-suspended in 80µl cold MACS buffer. Anti-IFN-γ PE 
was added and incubated on ice for 10 min. Cells were centrifuged at  for 5 
min at 4°C and re-suspended in cold MACS buffer. Anti-PE beads were added and 
incubated on ice for 15 min. Cold MACS buffer was added. Cells were centrifuged at 
 for 5 min at 4°C and re-suspended in cold MACS buffer. Magnetic columns 
were washed with MACS buffer. Cells with magnetic beads were added into magnetic 
columns placed in magnet. Columns were taken out of the magnet and washed with 
MACS. IFN-γ positive cells were centrifuged at  for 5 min at 4°C.  
 
2.3.14. Cloning by limiting dilution  
 
IFN-γ positive cells were re-suspended in media. Lymphocytes were isolated from 
apheresis cones (National Blood Service, Birmingham, UK) using density gradient 
centrifugation as described in section (numbers). Lymphocytes from three apheresis 
cones were mixed and pulsed with 10µg/ml of PHA for 1 hour at 37°C. Cells were then 
washed twice at  for 5 min at room temperature. Lymphocytes were gamma-
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irradiated with 40 Gy and washed 3-4 times at  for 5 min at room 
temperature. IFN-γ positive cells at concentration of either 0.3 cell/well or 1 cell/well 
were combined with buffy cells at (100,000 buffy cells/well). Anti-CD3 (clone OKT3) 
was added at a concentration of 30 ng/ml. These preparations were added to round 
bottom plates at 100 µl per well. After 2 days 100 µl MLA with IL-2 was added into 
each well and potential T cell clones were incubated at 37°C for 3 weeks. 
 
2.3.15. Identification of potential clones 
 
After 3 weeks round bottom cloning plates were visually screened for potential clones. 
Approximately 50 µl from potential clones were transferred onto round bottom 96 
well plates and washed four times at  for 5 min and re-suspended in media. 
Potential clones were split in duplicates peptide pulsing one well at concentration of 2 
µg/ml and adding media to second well as negative control. Plates were incubated 
overnight at 37°C. Responses from potential T cell clones to predicted T cell epitopes 




Responses from potential T cell clones to predicted T cell epitopes were assessed using 
ELISA assay. Maxisorb plates were treated with primary IFN-ƴ antibody (Pharmingen 
anti-human IFN-ƴ 18891D, Thermo scientific, USA) at concentration of 0.777 µg/ml and 
incubated overnight at 37°C. Treated plates were blocked with blocking buffer and 
incubated for 1 hour and 30 min at room temperature.  Plates were washed in 0.05% 
Tween/PBS solution five times. Onto the plates IFN-ƴ standards were added at 
concentration of 4000, 2000, 1000, 500, 250, 125, 62.5, 31.25 and zero pg/ml, and 
samples. Plates were incubated for 3 hours at room temperature. Plates were washed 
in 0.05% Tween/PBS solution five times. Secondary IFN-ƴ antibody (Pharmingen 
biotinylated anti-human IFN-ƴ 188902D, Thermo scientific, USA) was added at 
concentration of 0.375 µg/ml and plates were incubated for 1 hour at room 
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temperature. Plates were washed in 0.05% Tween/PBS solution six times. Extra-avidin 
peroxidase was added diluted in 1% BSA/PBS/0.05% Tween/PBS solution in dilution 
factor 1:1000 and plates were incubated for 30 min at room temperature. Plates were 
washed in 0.05% Tween/PBS solution eight times. Tetramethylbenzidine (TMB) 
substrate was added and plates were left to develop for 30 min at room temperature. 
Reaction was stopped with HCl/dH2O solution. Plates were read at 450 nm on 
microplate reader (Bio-rad, model 680). 
 
2.3.17. Rapid expansion protocol (REP) 
 
T cell clones that responded to peptide were transferred from cloning plates into 24 
well plates and expanded using the rapid expansion protocol (REP). Lymphocytes from 
three apheresis cones were prepared as described in section 2.3.14. Autologous 
lymphoblastoid cell line (LCL) were pulsed with 2 µg/ml of peptide for 1 hour at 37°C 
and gamma-irradiated with 40 Gy. In order to expand T cell clones mixture was 
prepared containing 1 million lymphocytes, 100,000 LCLs with monkey leukocyte 
antigen (MLA) and IL-2. T cell clones were added into wells and incubated at 37°C.    
 
2.3.18. Characterisation of T cell clones: Flow cytometry 
 
T cell clones were transferred into tubes containing MACS buffer and centrifuged at 
 for 5 min and re-suspended in MACS buffer. T cell clones were incubated 
with the following monoclonal antibodies for 20 min at room temperature; CD8 FITC, 
CD4 APC, CD3 APC-cy7 (Pharmingen, San Diego, USA) and washed and re-suspended in 
MACS buffer. Cell preparations were read on a flow cytometer (BD FACS CANTO II, BD 
Biosciences) collecting 10,000 gated lymphocytes. The flow cytometer was regularly 
calibrated using Calibrite beads (BD Biosciences, San Jose, USA) and compensation 
adjustments were made using single labelled antibody tubes. Data were analysed using 
FlowJo7 (Tree Star, Inc., Ashland, OR). The lymphocyte population was gated on the 
forward versus side-scatter. Viable cells were gated on the basis of 7-
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aminoactinomycin D (7-AAD) viability dye exclusion and examined for CD3 and CD4 or 
CD8 expression.  
2.3.19. Characterisation of CD8+ T cell clones: HLA class-I restriction 
 
Aliquots of clones 56 and 58 were washed twice in media at  for 5 min at 
room temperature and cells were counted. Approximately 2500 CD8+ T cells were 
transferred into duplicate wells of a round bottom 96-well plate. T cells were 
incubated overnight with media (negative control), peptide-pulsed autologous LCLs, or 
a panel of peptide-pulsed LCLs from donors. LCLs were selected to match the HLA 
class-I type of clones at one or two alleles. LCLs were incubated with 2 µg/ml of the 
relevant peptide pool for 1 hour at 37°C and washed four times in media at  
for 5 min at room temperature, and approximately 25,000 LCLs added to T cells. Plates 
were incubated at 37°C overnight. After approximately 18 hours, media was carefully 
removed and assayed for IFN-ƴ by ELISA. 
 
2.3.20. Characterisation of CD4+ T cell clones: recognition of lytic LCLs 
 
Prior to establishing whether clones were CD4+ or CD8+ by flow cytometry, initial 
screening experiments (not included in this thesis) showed that clones responded to 
peptide-pulsed LCLs from a number of laboratory donors. Once it was established 
clone 28 was CD4+, these cells were used to examine whether BcLF1-specific T cells 
recognised lytic LCLs derived from donor LCLs known to elicit a response. It was not 
within the scope of this thesis to undertake a full HLA class-II restriction.  An aliquot of 
clone 28 was washed twice in media at  for 5 min at room temperature and 
cells were counted. Approximately 2500 CD4+ T cell clones were transferred into 
duplicate wells of a round bottom 96-well plate. T cells were incubated overnight with 
either media (negative control), BZLF1 knock out LCLs, B95.8 LCLs (10% lytic), B95.8 
LCLs pulsed with peptide pool 5, or peptide pool 5 alone. LCLs used for lytic recognition 
were provided by a colleague, and were previously shown to be lytic by BZLF1 staining 
and flow cytometry (data not shown). LCLs were washed twice in media at  
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for 5 min at room temperature, counted, and approximately 25,000 cells added to 
relevant wells. Peptide pulsed LCLs were incubated with 2 µg/ml of peptide for 1 hour 
at 37°C and washed four times in media at  for 5 min at room temperature. 
Plates were incubated at 37°C overnight. After approximately 18 hours, media was 
carefully removed and assayed for IFN-ƴ by ELISA. 
 
2.4. Molecular Biology Techniques 
 
Peptides from BcLF1 and BPLF1 were 20-mers that contained either an HLA-A*02 or 
HLA-B*07 predicted T cell epitope. Although predicted T cell epitopes may have some 
overlap with other HLA-restrictions, for future work, it would be desirable to screen 
donors independent of HLA-type. A more appropriate screening strategy is using a 
whole protein approach. Prior to the start of this project the BcLF1 had already been 
inserted into an appropriate vector. The aim of the molecular part of this project was 
to insert BPLF1 (and the invariant chain so that CD4+ T cell responses could be 
examined) into a vector. 
 
2.4.1. Polymerase chain reaction (PCR) 
 
For BPLF1 to be successfully inserted into a vector we had to first successfully amplify 
the BPLF1 gene. As BPLF1 is a relatively large gene with 9.5 kb (Whitehurst et al., 2012) 
we decided to amplify it in quarters. Polymerase chain reaction (PCR) was used to 
amplify BPLF1 and therefore, primers were designed using NCBI Primer Blast tool (Ye 
et al., 2012) (see table 4) obtaining four quarters of BPLF1. The annealing regions for 
amplifying the quarters of BPLF1 protein are shown in figure 5. Expand Long Template 
PCR System was used with different buffers and Phusion High-Fidelity PCR Kit. A PCR 
thermal cycler (Life technologies, Applied Biosystems GeneAmp PCR System 9700) was 
used and programmed with the following conditions: 35 cycles at 94°C for 2 min for 
initiation, at 94°C for 30 sec for denaturing, at 55°C for 30 sec for annealing, at 72°C for 
1min/kbp for elongation, at 72°C for 7 min for final elongation. The obtained PCR 
amplicons were maintained at 4°C until electrophoresis. 
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Table 4: BPLF1 primer sequences. 
Quarter 5’ – 3’ sequence 3’ – 5’ sequence 
Quarter 1 ccgaagatgagtaacggcga aaacaagggaagagcgggagag 
Quarter 2 agtagggaccgatcgtctgtg aaaagacgagcagccgaggct 
Quarter 3 gacatgaaatcagcggtggtc cggcccctaactctctttgtc 





Figure 4: Schematic diagram of BPLF1 with primer positions. 
 
 
2.4.2. Electrophoresis  
 
The obtained PCR amplicons of BPLF1 were electrophoresed on a 1.5% low melting 
point agarose (LMPA) gel and visualized by ethidium bromide staining (EtBr). Gel for 
electrophoresis was a mixture of agarose powder at concentration of 1.5 g mixed with 
98 ml of distilled water, 2 ml of 50x TAE and 5 µl of EtBr. Amplicons were mixed with 
loading dye before adding 5 µl onto agarose gel. Amplicons were electrophoresed for 
30 - 45 min (120V). The DNA Molecular Weight Marker X (Roche) was used as the 
orientation marker of DNA separation. The DNA separation was visualized using a UV 
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2.4.3. Ligation of invariant chain into pENTR1A plasmid  
 
In order to insert BPLF1 into virus vector the invariant chain had to be inserted into 
appropriate vector first and as a vector the pENTR1A plasmid was used. The pENTR1A 
vector, containing kanamycin resistance gene, was cut at restriction sites with the 
restriction enzymes Sal-I and Xho-I. The antarctic phosphatase was added to neutralize 
phosphate ends. Restriction enzymes were inactivated by heating to 65°C for 20 min. 
The invariant chain (synthesised by GeneArt) was cut with the restriction enzyme Xho-I 
and heated to 65°C for 20 min to neutralize restriction enzyme. The pENTR1A vector 
and the invariant chain were combined together in microcentrifuge tube in a ratio of 
1:2 and incubated at 25°C for 5 min to obtain ligation constructs (see figure 5).  
 
 
Figure 5: Schematic diagram of ligation of the Invariant chain into pENTR1A plasmid. 
Bajt T. Towards a prophylactic Epstein Barr Virus (EBV) vaccine to prevent EBV-associated malignancies 
and infectious mononucleosis. MRes thesis, University of Birmingham, 2013. 




2.4.4. Transfection of modified pENTR1A plasmid into competent cells  
 
The obtained ligation constructs, positive control containing kanamycin resistance 
gene (GFP-LC3 plasmid) and the negative control (pENTR1A plasmid) were used to 
transfect competent cells (E. Coli).  The ligation products, GFP-LC3 plasmid and 
pENTR1A plasmid were added into separate microcentrifuge tubes. The competent 
cells were added into each microcentrifuge tube and the mixtures were incubated on 
ice for 30 min. Microcentrifuge tubes were transferred into the water bath and 
incubated at 42°C for 30 sec and transferred on ice for one minute (heat shock). The LB 
media was added into microcentrifuge tubes and competent cells were transferred 
into a rotary shaker for 1 hour at 37°C, 5% CO2. The competent cells were plated onto 
agar plates, containing kanamaycin antibiotic at concentration of 100 µl/ml, and 
incubated overnight at 37°C, 5% CO2.  
 
2.4.5. Colony selection    
 
The competent cells containing kanamaycin resistance gene expanded into colonies 
which were selected and transferred into tubes, single colony per tube. The LB media 
was added with kanamycin antibiotic at concentration of 100 µl/ml. The culture was 
incubated overnight in rotary shaker at 37°C, 5% CO2.  
 
2.4.6. Plasmid DNA purification and DNA digestion 
 
After the overnight incubation the colonies expanded. In order to obtain plasmid DNA 
from competent cells the DNA was purified using QIAprep spin miniprep kit (QIAGEN, 
Sussex, UK). The cultured competent cells were transferred in microcentrifuge tubes 
and centrifuged at  for 30 sec. Competent cells were re-suspended in 
buffer P1. The buffer P2 was added and cultures were thoroughly mixed. The buffer N3 
was added lizing the competent cells. The mixtures were centrifuged at  
for 10 min. Supernatant from each microcentrifuge tube was transferred onto the 
QIAprep spin columns and centrifuged at  for 30 sec. Onto the columns the 
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PE washing buffer was added and QIAprep spin columns were centrifuged at 
 for 30 sec. QIAprep spin columns were placed in a clean microcentrifuge 
tube adding buffer EB and left for a minute and centrifuged at  for a minute. 
Purified DNA was digested with the restriction enzymes Xba-I and Not-I to identify 
whether the invariant chain has been correctly ligated into the pENTR1A plasmid. 
Furthermore, the Nco I and Eco-RV were used to identify the orientation of the 
invariant chain. The digested DNA constructs were electrophoresed in a 2% agarose gel 
and visualized by ethidium bromide staining at 140V for 25 min. After the identification 
of potential constructs containing the invariant chain with sense orientation, 
constructs were sent for a DNA sequencing (School of Biosciences, University of 
Birmingham, UK) to obtain the DNA sequences. 
 
2.4.7. Preparation of DNA constructs for electroporation 
 
At standard “heat shock” method of transfection described in section 2.4.4 we 
obtained very low transfection efficiency. Therefore, we decided to use 
electroporation to increase the transformation.   
The ligation constructs were modified as described in section 2.4.3. Constructs were 
electrophoresed in a 2% agarose gel and visualized by ethidium bromide staining. The 
constructs were visualized by the UV light and cut out of agarose gel. To extract 
obtained constructs the QIAquick Gel Extraction Kit (QIAGEN, Sussex, UK) was used. 
The constructs in agarose gel were transferred into microcentrifuge tube and buffer 
QG was added. Microcentrifuge tube with ligation constructs (DNA samples) was 
incubated at 50°C for 10 min. Isopropanol was added and the DNA samples were 
transferred to the QIAquick column and washed three times by centrifuging at 
 for 1 minute using buffer QG and buffer PE. The flow-through was 
discarded and QIAquick column was centrifuged at  for 1 minute. The 
QIAquick column was transferred onto new clean microcentrifuge tube and elution 
buffer was added. Microcentrifuge tube with DNA samples was centrifuged at 
 for 1 minute. The purified DNA was quantified using nanodrop 
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spectrophotometer (Thermo Scientific, Wilmington, USA) and transferred into 
microcentrifuge tube with prepared NEB 5-alpha electrocompetent cells (E. Coli) (New 
England Biolabs).  
 
2.4.8. Electroporation of E. Coli electrocompetent cells 
 
Electrocompetent cells were cultured in LB media overnight in rotary shaker at 37°C, 
5% CO2 and transferred into fresh LB media and incubated in a rotary shaker until 
OD600nm was approximately 0.4 measuring by spectrophotometer. The 
electrocompetent cells were centrifuged at  for 10 min at 4°C, re-suspended 
in ice-cold sterile distilled water and washed three times at  for 10 min at 
4°C. Cells were aliquoted into ice-cold electroporation cuvets and pre-cold DNA was 
added. The electroporation cuvets containing electrocompetent cells and ligation 
constructs (DNA) were incubated on ice for 30 min and placed into electroporation 
apparatus (Bio-Rad Gene Pulser). Electroporation apparatus was set to 2.5 kV, 25µF 
and 200 Ω and DNA/cells mix was pulsed. After the electroporation the LB media was 
added into cuvets. The electrocompetent cells were grown on agar plates, containing 
kanamaycin antibiotic at concentration of 100µl/ml, and incubated overnight at 37°C, 
5% CO2. The colonies were selected and plasmid DNA was purified and digested as 
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3.1. Cellular Biology results 
 
To study T cell responses to selected proteins MCP, encoded by BcLF1, and LTP, 
encoded by BPLF1, nine donors were screened from wide range of the HLA-class I 









Figure 6: Donor HLA-class I type. In ex-vivo and in-vitro experiments nine donors from wide 
range of HLA-class I types were screened for T cell responses. Question mark (?) denotes that 
the HLA-class I type is not known.   
 
3.1.1. Ex-vivo T cell responses to predicted T cell epitopes of EBV proteins 
MCP and LTP  
 
The IFN-ƴ ELISPOT assay was used to examine whether T cell responses to predicted T 
cell epitopes of EBV proteins MCP and LTP were detectable ex-vivo. PBMCs from seven 
EBV-seropositive healthy donors were tested for five MCP peptide pools containing 
three to four T cell epitopes per pool, and six LTP peptide pools containing four to five 
epitopes per pool. The full list of peptide pools is presented in table 2. The 
quantification of IFN-y producing T cells was conducted after an overnight incubation. 
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On average donors responded to 3/5 MCP peptide pools and 4/6 LTP peptide pools. 
The majority of ex-vivo T cell responses measured were small under 60 spots/million 
cells (figure 8). Donor 1 showed no detectable response ex-vivo. Donor 5 and 8 
responded to all 11 pools when measured ex-vivo. Donor 5 T cell responses to pools 4 
– 7 were low, below 60 spots/million cells and to pools 1 - 3 and 8 - 11 ex-vivo 
responses were of medium size (61 -120 spots/million cells) to very high (>181 
spots/million cells). The largest ex-vivo T cell response was seen in donor 5 in pools 10 
and 11 representing responses to predicted T cell epitopes of EBV protein LTP (see 











Figure 7: Donor 5 ex-vivo example. Figure presents ex-vivo T cell responses to predicted T cell epitopes. 
Donor 5 showed a large response to positive control - PHA (>1200 spots/million cells) and no response 
to negative control – DMSO suggesting there was no background. Donor 5 responses to pools 1 and 5 
were low (below 70 spots/million cells) whereas responses to pools 3 and 11 were medium (156 
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Legend: Figure represents ex-vivo responses to predicted T cell epitopes 
as spots/million cells (PBMCs). Donor 3 and 9 were not included when 
measuring ex-vivo T cell responses for technical reasons. The figure shows 
the number of stimulating pools with magnitude of response.  
 
Figure 8: Ex-vivo donor responses to T cell peptide pools of EBV proteins MCP and LTP. The responses 
are presented as mean value of both duplicate wells after subtracting the values of negative control 
(DMSO). The DMSO values ranged between 0 to 16 spots/million cells. 
 
 
Ex-vivo analysis of T cell responses to control peptides (see table 3) showed that 
donors exhibit an EBV-specific immune response, even in the absence of an MCP or 
LTP specific response. For each donor two control peptides were selected on the basis 
of past experiments (data not shown). As can be seen from figure 9, all donors with the 
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Legend: Figure represents ex-vivo responses to predicted T cell 
epitope control peptides as spots/million cells (PBMCs). Donor 3 and 




Figure 9: Ex-vivo donor T cell responses to control peptides. For each donor there were two control 
peptides selected for determination of reliability of IFN-ƴ ELISPOT assay. Donor T cell responses to 
control peptides were low (responses to RPP and CLG control peptides in donors 2, 4 and 5) to large 
(responses to FLR, YVL, RPP and CLG in donors 2, 5, 6, 7 and 8). In donors 2, 4 and 6 there were no 
response to control peptides CLG, YVL and QPR. The quantified responses are presented as mean value 
of both duplicate wells after subtracting the values of negative control (DMSO). 
 
3.1.2. In-vitro T cell responses to predicted T cell epitopes of EBV proteins 
MCP and LTP 
 
As T cell responses to MCP and LTP were low and on the limit of detection ex-vivo, a 7-
day cultured IFN-ƴ ELISPOT was used to confirm the initial results. It was anticipated 
that very low frequency responses would expand to a detectable level. PBMCs from 
nine EBV-seropositive healthy donors were cultured as described in section 2.3.10. The 
T cell responses to five MCP peptide pools containing three to four T cell epitopes per 
pool, and six LTP peptide pools containing four to five epitopes per pool were 
examined with IFN-ƴ ELISPOT. After 7 days, cells were washed, and transferred onto 
ELISPOT plates. One of the duplicate wells was re-challenged with peptide, the other 
well, which had seen peptide 7 days prior, served as a negative control. The 
quantification of IFN-y producing T cells was conducted after an overnight incubation. 
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Figure 10: Donor 3 in-vitro example. Figure presents in-vitro T cell responses to predicted T cell epitopes 
from donor 3. Donor 3 showed a large response to positive control - PHA (>1200 spots/million cells) and 
low response to negative control. Donor 3 showed no response to pool 6 and a low response to pool 4 
(below 100 spots/million cells) whereas responses to pools 8 and 2 were medium (120 spots/million 
cells) to high (404 spots/million cells). On the figure only one duplicate well is presented as the second 
duplicate well was a negative control and all values presented are subtracted from negative controls.  
 
On average, in vitro data showed that donors responded to 3/5 MCP peptide pools and 
4/6 LTP peptide pools. The in-vitro T cell responses ranged between 4 spots/million 
cells up to 404 spots/million cells and the majority of T cell responses were low under 
100 spots/million cells. However, there was a clear increase in number of T cell 
responses defined as being of ‘medium’ intensity, ranging from 100 to 300 
spots/million cells.  
Interestingly, donor 1 showed T cell responses to four peptide pools of MCP 
and five peptide pools of LTP and in peptide pools 6 and 10 T cell responses were 
ranked as medium despite the fact that in ex-vivo there were no detectable T cell 
responses.  
In donor 2 there was an increase in T cell response. For example, in peptide 
pool 3 where 8 spots/million cells were detected ex-vivo, there was 172 spots/million 
cells detected in-vitro experiment. In peptide pool 6, where there was, interestingly, 
no response detected in ex-vivo experiment, in in-vitro experiment there was a 
medium response. The low responses seen in peptide pools 5, 8 and 10 when 
measured ex-vivo were undetectable when measuring in-vitro T cell responses.  
The T cell responses in donor 3 were low to high in peptide pool 2 with 404 
spots/million cells (see figure 10).  
In donor 4 there was an appearance of a low T cell response in peptide pool 1 
which was not detected ex-vivo but T cell responses seen in peptide pools 2, 7 and 8 
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were undetectable when measuring in-vitro T cell responses. The remaining T cell 
responses detected ex-vivo have when measured in-vitro increased.  
Donor 5 responded to all peptide pools ex-vivo however, in-vitro T cell 
responses to peptide pools 3, 7 and 8, were no longer detectable.  
In donor 6 T cell responses seen ex-vivo expanded except in peptide pools 4 and 
6 where the T cell responses measured ex-vivo were no longer detectable in-vitro. 
Furthermore, in donor 7 all T cell responses detected ex-vivo expanded however, the T 
cell response detected in-vitro in peptide pool 6 ranked as medium was ex-vivo not 
detected. In donor 8 the T cell responses in peptide pools 5 and 9 detected as low 
measured ex-vivo when measured in-vitro were no longer detected (see figure 11). 
Interestingly, in 3/4 donors where T cell responses in peptide pool 6 were 
undetectable ex-vivo the T cell responses became detectable when measuring in-vitro.  
 
 
Legend: Figure represents in-vitro responses to predicted T cell epitopes 
as spots/million cells (PBMCs). All nine donors were included when 
measuring in-vitro T cell responses. The figure shows number of the pools 
of each peptide donors responded to with magnitude of individual 
response.  
 
Figure 11: In-vitro donor responses to T cell pools of EBV proteins MCP and LTP. 
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In in-vitro ELISPOT assay control peptides were also used to assess EBV-specific 
immune response, even in the absence of an MCP or LTP specific response. The same 
control peptides were used as for the ex-vivo experiment.  
In donor 1 when measured ex-vivo there were no T cell responses detected to 
control peptides CLG and YVL however, in in-vitro there were medium T cell responses. 
In donors 2 and 3 there was an increase in T cell response from measuring ex-vivo to 
in-vitro to control peptide RPP whereas, in donor 7 increase was seen in both control 
peptides. However, in donor 8 T cell responses to control peptides CLG and YVL 
decreased when measuring in-vitro.   
The T cell responses to control peptide QPR when measured ex-vivo were 
undetectable but there were T cell responses detectable in-vitro in donors 3 and 6. 
However, in donor 5 T cell responses were changing in the opposite manner as there 
were a low T cell responses to control peptide CLG ex-vivo but in-vitro the T cell 
responses were no longer detected.  In donor 9 medium T cell responses were 






Legend: Figure represents in-vitro responses to predicted T cell epitope 
control peptides as spots/million cells (PBMCs). All nine donors were 
included when measuring in-vitro T cell responses. 
 
 
Figure 12: In-vitro donor T cell responses to control peptides. For each donor there were two control 
peptides selected for determination of reliability of IFN-ƴ ELISPOT assay.  There was no T cell responses 
detected for control peptide CLG in donor 5. Approximately the same number of donor T cell responses 
were characterised as medium or high. The highest T cell responses were observed for control peptides 
HPV (donor 3), YVL and CLG (donor 7). Only the T cell responses in re-challenged wells are presented on 
the figure. The magnitudes presented are obtained after subtracting from the negative control which 
was in this case the non re-challenged well.  
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Donor T cells responded to a different number of peptide pools when measured ex-
vivo and in-vitro. The responding number of pools stayed roughly stable from ex-vivo 
to in-vitro experiment (see table 5). 
 
Table 5: Number of peptide pools eliciting a response in donors. N/A denotes that data was not 











The T cell responses measured ex-vivo and in-vitro were compared in seven donors as 
in donor 3 and 9 ex-vivo ELISPOT was not performed. Table 6 presents expansion in T 
cell responses which expanded from 11 to 97-fold. The highest expansion was 
observed in donor 1 and the lowest expansion in donor 6 (see table 6).   
 
Table 6: Average fold expansion in T cell responses from ex-vivo to in-vitro experiment. T cell 
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3.1.3. CD4+ and CD8+ T cell responses to MCP and LTP peptides 
 
 To determine which subset of T cells (CD4+ T cells and/or CD8+ T cells) responded to 
predicted T cell epitopes from EBV proteins MCP and LTP, four representative donors 
were re-examined. Polyclonal T cell lines were established using peptide pools known 
to elicit an IFN-y response. The CD4+ T cells were isolated and preparations were 







Figure 13: Examples of CD4+ and CD8+ T cell responses. The CD4+ and/or CD8+ T cell responses were 
measured with INF-ƴ ELISPOT assay with peptide pools known to elicit an IFN-y response in donors 1, 2, 
3 and 7. In donors 1 and 2 the separation in T cell subset responses is clear, as in donor 1 T cell 
responses are seen only in CD8+ T cells and in donor 2 only in CD4+ T cells. In donors 3 and 7 T cell 
responses are seen in both subsets of T cells.  
 
In two donors (donor 1 and 2) the separation in responses of T cell subsets was clearly 
seen as in donor 1 there was a large predominant CD8+ T cell response to the peptide 
pool 5 and in donor 2 the T cell response to peptide pool 3 was predominant in CD4+ T 
cells. Whereas, in two donors (donor 3 and 7) responses to predicted T cell epitopes 
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Figure 14: Responses of T cell subsets to peptide pools. To identify which T cell subsets responded to 
peptide pools donor T cells (donor 1, 2, 3 and 7) were screened with peptide pools known to elicit an 
IFN-y response. In donors 1 and 3 experiment was repeated three times, in donor 2 two times and in 
donor 7 the experiment was repeated four times. Values are presented as mean values obtained in all 
four experiments. The asterisk (*) denotes that peptide pool belongs to MCP and hashtag (#) denotes 




Following limiting dilution assay, 145 potential clones were identified established from 
donor 1. Potential clones were examined for IFN-y responses to the stimulating 
peptide pool by IFN-Y ELISA. 11 clones showed IFN-y responses above background 
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3.1.5. Characterisation of T cell clones 
 
After two weeks, T cell clones were examined for CD4 or CD8 expression by 
fluorescence-activated cell sorting (FACS). Figure 15 shows representative dot plots 
from two clones. Five clones were CD4+ and six were CD8+. 
 
 
Figure 15: Flow cytometry analysis of T cell clones. Lymphocytes were gated on the forward versus 
side-scatter. Viable cells were identified on the basis of 7-aminoactinomycin D (7-AAD) exclusion (viable 
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3.1.6. HLA restriction of T cell clones 
 
The CD8+ T cell clones were assessed for IFN-ƴ production in response to peptide. 
Selected LCLs from seven donors and autologous LCLs were pulsed with peptide. Two 
CD8+ T cell clones (56 and 88) are presented in figure 16. LCLs were selected to share 
only one or two HLA-alleles with the representative donor from which CD8+ T cell 
clones were derived. The CD8+ T cell clones 56 and 88 showed a low responses when 
measuring released IFN-ƴ with 750 and 1300 pg/ml when combined with presenting 
autologous LCLs. But overall the responses from clones 56 and 88 when combined with 
LCLs 1-6 were low suggesting this CD8+ T cell clones were not HLA-A2, HLA-A*24, HLA-
B*39 or HLA-C*07. When CD8+ T cell clones were combined with LCLs from LCL-donor 
7 there was a large IFN-ƴ response with 742 pg/ml in CD8+ T cell clone 56 and 1222 
pg/ml in CD8+ T cell clone 88. Data obtained from IFN-ƴ ELISA assay therefore showed 
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Figure 16: The CD8+ T cell clones HLA-restriction.  The figure presents HLA types of presenting LCLs and the IFN-ƴ responses obtained from CD8+ T cell clones 56 and 88. 
Responses from autologous LCLs and LCLs from LCL-donors 1-6 were low. However, the response when combined with LCLs from LCL-donor 7 were large. Therefore, data 
showed that CD8+ T cell clones 56 and 88 are HLA-C*06 restricted. This experiment was conducted in duplicates and average values are presented.   
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3.1.7. Recognition of lytic LCLs  
 
 
The CD4+ T cell clones were assessed to see whether clones recognised lytic LCLs. In 
the assay latent and lytic LCLs were used to assess whether CD4+ T cell clones 
recognise lytic LCLs. As marker of potential infection media was used. When CD4+ T 
cell clones were combined with latent LCLs there were no IFN-ƴ released. However, 
large responses were observed when CD4+ T cell clones were combined with latent 
LCLs and peptide pool 5 or only with peptide pool 5. When CD4+ T cell clones were 
combined with lytic LCLs there were an IFN-ƴ released. Data obtained from IFN-ƴ ELISA 













Figure 17: The CD4+ T cell clones recognition of lytic LCLs. To confirm that LCLs were in lytic cycle 
staining for BZLF1 was performed and LCLs were inspected by flow cytometry. Approximately 10% of 
LCLs in the culture were lytic (data not shown). Data obtained suggests that the CD4+ T cell clones 
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3.2. Molecular biology results 
 
3.2.1. Amplification of BPLF1 gene 
The BPLF1 gene which is approximately 9.5 kb long was amplified in quarters to be 
inserted into an appropriate vector which would allow screening of the T cell 
responses with a whole protein regardless of the HLA-type. The BcLF1 gene encoding 
the MCP was successfully inserted into a vector before the start of this project. In 
order to optimise the reaction different kits and buffers were used. The Expand Long 
Template (ELT) PCR System with buffers 1 and 3, and Phusion High-Fidelity (HF) PCR Kit 
were used.  The ELT buffer 1 is used for amplification of fragments from 0.5 to 12 kb 
whereas buffer 3 is used for amplification of fragments longer than 15 kb. We decided 
to optimise our reaction with this buffer even so our fragments were approximately 8 
kb long. The Phusion High-Fidelity PCR Kit contains High-Fidelity DNA Polymerases 
which is used for long or difficult amplifications.  
 
Quarters 1 and 4 were successfully amplified using the Expand Long Template (ELT) 
PCR System with buffers 1 and 3 with addition of dimethyl sulfoxide (DMSO) as 
presented on figure 18. The successfully obtained amplicons are seen as lines which 
can be visible between 3054 bp and 2036 bp mark. For further experiments quarters 1 








Figure 18: PCR amplicons of BPLF1 quarter 1 and 4. Quarter 1 and quarter 4 were amplified using 
Expand Long Template PCR System (ELT) with added dimethyl sulfoxide (DMSO) and buffer 1 or buffer 3 
and electrophoresed on 1.5% LMPA gel. Quarters are visual between 3054 bp and 2036 bp mark. The Q1 
and Q4 denotes quarter 1 and quarter 4.  
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Quarters 2 and 3 were successfully amplified using the Phusion High-Fidelity (HF) PCR 
Kit with addition of dimethyl sulfoxide (DMSO) as presented on figure 19. The 
successfully obtained amplicons are seen as lines which can be visible between 3054 
bp and 2036 bp mark. For further experiments all four amplified quarters were meant 









Figure 19: PCR amplicons of quarter 2 and 3 on 1.5% LMPA gel. Quarter 2 and 3 were amplified using 
Phusion High-Fidelity PCR Kit (Phusion HF) with added dimethyl sulfoxide (DMSO) and electrophoresed 
on 1.5% LMPA gel. Quarters are visual between 3054 bp and 2036 bp mark. The Q2 and Q3 denotes 
quarter 2 and quarter 3. 
 
3.2.2. Insertion of invariant chain into a vector 
 
 
The first step of molecular cloning involved insertion of invariant chain into 
appropriate vector allowing screening for CD4+ T cell responses. After successfully 
inserted invariant chain we would continue with second step which involved molecular 
cloning of amplified BPLF1 gene quarters into appropriate vector already containing 
invariant chain. The cloning process was repeated three times in order to increase 
transformation efficiency as presented on figure 20. In third experiment we used 
electroporation and transformation efficiency increased for approximately 3.7-fold in 
comparison to second experiment and 200-fold in comparison to the first experiment 
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Figure 20: Transformation efficiency (T/µg). Figure presents transformation efficiency of all 
experiments. Data presented was obtained from three experiments. Asterisk (*) denotes transformation 
efficiency in experiment three where electroporation was used. With use of electroporation 
transformation efficiency increased dramatically as it was 3.7-fold higher in comparison to second 
experiment and as high as 200-fold in comparison to the first experiment. 
 
  
After transformation DNA samples with potential constructs containing invariant chain 
were selected and digested as described in section 2.4.6 to identify DNA samples 
containing plasmid pENTR1A with invariant chain. Samples containing invariant chain 
were identified as the invariant chain in the DNA sample construct was seen as second 












Figure 21: Identification of samples containing invariant chain. Example figure presents purified DNA 
samples on agarose gel. Samples containing potential successfully obtained plasmid pENTR1A with 
invariant chain are visualised as second line below 220 bp. Numbers (15 – 29) denote sample number.  
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Furthermore, DNA samples with potential constructs containing invariant chain were 
digested as described in section 2.4.6 to identify the orientation of inserted invariant 
chain. Invariant chain in sense orientation was on agarose gel visualised as a second 




Figure 22: Identification of invariant chain orientation. Example figure presents purified DNA samples 
on agarose gel. Samples containing plasmid pENTR1A with invariant chain in sense orientation are 
visualised as a single line below 517 bp. Numbers (15 – 29) denote sample number.  
 
 
The identified DNA samples containing invariant chain in sense orientation were sent 
for a DNA sequencing and DNA sequences were obtained (data not shown). However, 
despite positive identification of DNA samples on agarose gel non of the sequenced 
DNA samples contained the right DNA sequence. Therefore, we did not achieve the 
aim of successfully inserting the BPLF1 gene into the vector in the duration of this 
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EBV is one of the eight human herpesviruses that infects >90% of the world 
population. Most people are infected without knowing it as they become infected 
during infanthood presenting no symptoms. EBV is also classified as group 1 agent – 
carcinogenic to humans (Taylor and Blackbourn, 2011) and is one of the oncoviruses 
(Schiller and Lowy, 2010, Butt and Miggin, 2012). In 2008 there were approximately 
200,000 new cases (10%) of EBV associated malignancies worldwide (Cohen et al., 
2011, de Martel et al., 2012) therefore, prevention of primary infection is important 
and novel vaccines need to be developed as past EBV vaccine attempts have failed. 
However, two successful examples of vaccines consisting of surface antigens (i.e. 
hepatitis B surface antigen HBsAg in hepatitis B vaccine (Keating and Noble, 2003)) and 
capsid proteins (i.e. major capsid protein L1 of human papilloma virus types 6, 11, 16 
and 18 in quadrivalent HPV vaccine (Bryan, 2007)) are very encouraging. The aim of 
this thesis was to investigate T cell responses in healthy EBV-seropositive donors to 
two EBV structural proteins MCP, encoded by BcLF1, and LTP, encoded by BPLF1. The 
MCP is the largest among EBV capsid proteins and the LTP is the largest among EBV 
tegument proteins (Johannsen et al., 2004). Despite of the fact that this two proteins 
are large and abundantly expressed their importance at primary infection is still poorly 
understood. Therefore, it was necessary to investigate MCP and LTP potency as 
possible targets of future prophylactic EBV vaccine which would prevent EBV-
associated malignancies and infectious mononucleosis.  
 
The results of the cellular part presented in this thesis have shown that T cells obtained 
from healthy EBV-seropositive donors do respond to MCP and LTP epitopes. Moreover, 
T cell responses expanded after 7 days of culture. Furthermore, after CD4+ T cell 
depletion from four representative donors we have observed predominant T cell 
responses from one subset of T cells (CD4+ or CD8+ T cells) in two donors. In other 
donors we have observed responses from both subsets of T cells. We successfully 
established T cell clones specific for MCP from one representative donor (donor 1) and 
determined whether clones were CD4+ or CD8. Subsequently, CD8+ T cell clones 56 
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and 88 were HLA-restricted showing that they were HLA-C*06 restricted. Additionally, 
the results showed that CD4+ T cell clones recognised lytic LCLs. Overall, the work 
suggests that the MCP and LTP do elicit immunogenic T cell responses in healthy EBV-
seropositive people highlighting the potential of structural proteins as EBV vaccine 
targets. Based on the current work, the EBV structural protein BcLF1 might be a 
suitable candidate, if it can be established that T cells targeting this protein, recognise 
(and kill) cells infected with EBV early in the infective cycle (i.e. within 24 hours). 
 
The first question we addressed in cellular biology part of this project was whether 
people have T cells that recognise the MCP and LTP. It has been suggested that MCP is 
not expressed on the surface of infected cells in healthy EBV-seropositive people 
(Prang et al., 1997). However, the results of this project imply that T cells obtained 
from healthy EBV-seropositive donors do indeed recognise predicted epitopes of the 
MCP and LTP. For example, donor 1 did not exhibit a detectable ex-vivo response, 
however, after seven days of culture, responses were readily observed. Further, both 
CD4+ and CD8+ T cell clones were obtained from donor 1. In donor 5 we observed very 
high T cell responses to peptide pools 10 and 11 showing recognition of epitopes 
derived from the LTP. It can be confirmed that the results reported are not laboratory 
error: all values were compared to negative controls (DMSO) to rule out non-specific 
responses as a result of infection. Further, to monitor the reliability of the assay, 
control peptides from EBV proteins known to elicit a response in donors were used.  
 
The next question to address was whether the obtained ex-vivo T cell responses would 
expand over time, therefore T cells were cultured for 7 days. As expected, the 
responses from these in-vitro experiments were higher than ex-vivo responses. For 
example in donor 4, ex-vivo responses in peptide pool 10 were 8 spots/million cells. 
Following 7 days of culture, this donor exhibited a response of 324 spots/million cells. 
Therefore, results confirmed the expansion of T cell responses after 7 days of culture. 
Interestingly, T cell responses to some peptide pools were that were observed ex-vivo 
were undetectable in the in-vitro experiments. Considering that ex-vivo T cell 
responses were sometimes very low and close to the limit of detection, it is likely that 
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some responses were indeed spurious results. This highlights the utility of using the 
seven days of culture experiments to confirm responses. Indeed, some responses were 
not detected ex-vivo were detectable after expansion seven days later.  
 
Following the confirmation that T cells recognise epitopes derived from the MCP and 
LTP and that the T cell responses expand over time, the next question to address was 
which subset of T cells (CD4+ and/or CD8+ T cells) exhibits this response. For some of 
the EBV structural proteins relative immune-dominance for CD4+ and CD8+ T cell 
responses have already been determined. For example, the largest and most frequent 
responses come from latent proteins and are directed towards proteins such as EBNAs 
1, 2 and 3A (Hislop et al., 2007). However, CD4+ T cell responses have been so far less 
studied (Precopio et al., 2003). In only 4/11 peptide pools we observed clear 
dominance of T cell responses of only one subset of T cells. The responses derived 
from the CD8+ T cells. However, in other peptide pools the majority T cell responses 
derived from both subsets. This data was derived by separating CD4+ T cells using 
magnetic beads, and assaying the resulting CD4+ cells separately from the remainder 
(i.e., all other cells including CD8+). A possible reason for observing T cell responses in 
both pools of T cells might be due to impure separation of cells. Good practice would 
be to check the purity of isolated CD4+ T cells using flow cytometry, however this was 
not feasible in the current project. An alternative to separating CD4+ T cells using 
magnetic beads that might result in greater purity is sorting cells using a flow 
cytometric approach. 
 
Once it was established that healthy donors exhibit frequent T cell responses to the 
MCP and LTP the next part of this thesis aimed to generate and characterise T cell 
clones. We successfully obtained T cell clones specific for MCP but were unable to 
obtain LTP-specific clones. Cloning was undertaken using IFN-γ capture. MCP-specific T 
cells were obtained after the first attempt at cloning, whereas LTP-specific clones were 
not generated despite several attempts. It might be that an alternative enrichment 
strategy would yield different results, such as CD137 capture (for CD8+ T cells) and 
CD154 capture (for CD4+ T cells).  
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After successfully generating MCP-specific clones and expanding the cells, the project 
next undertook an HLA class-I restriction experiment. T cell clones 56 and 88 were 
HLA-C*06 restricted. The current work is novel by showing that an HLA-C*06 restricted 
epitope exists within the MCP. Unfortunately, it was beyond the scope of this project 
to identify the stimulating peptide within the pool of predicted T cell epitopes, nor was 
it possible to restrict the 20mer peptides down to the minimal 9mer epitope.  
 
The last question to address in cellular biology part of the project was whether CD4+ T 
cell clones specific for MCP recognise lytic LCLs. The results showed a very small 
response to the autologous latent (i.e., B95.8) LCLs, which likely represents the small 
number of LCLs in the lytic cycle. However, this response was barely above 
background. Importantly, there was a T cell response to lytic LCLs (of which 10% had 
been confirmed to be lytic). This response was clearly higher than the response to the 
latent LCLs, but much lower than the peptide-pulsed autologous LCLs. The relatively 
small response might suggest that there is a low natural expression of an epitope 
derived from the MCP on the surface of LCLs, or more likely reflects the small number 
(i.e., only 10% of cells). It should be considered that staining for the late antigen VCA 
might be a more accurate alternative to BZLF1 staining to establish how many LCLs are 
in lytic cycle. If it can be shown that the MCP is expressed to a high level on infected 
cells early in the infective cycle, and the frequent T cell response shown by the present 
study results in killing of infected cells, then structural proteins such as the MCP might 
warrant further investigation as vaccine candidates.  
 
The aims of molecular biology part of this project were to amplify the BPLF1 gene that 
encodes the LTP and to insert the invariant chain into the pENTR1A vector alongside 
BPLF1. The relevance of this part of the project was to create a tool to assess T cell 
responses to the LTP using a whole antigen approach that is independent of HLA-type. 
In the current project, we were able to amplify the BPLF1 gene by PCR in four quarters. 
Previous attempts at amplifying BPLF1 as the entire gene, or the gene split into two 
had failed (data not shown in this thesis) – likely due to the size of the gene. 
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Unfortunately we were not able to insert the invariant chain into pENTR1A vector, 
shown by incorrect DNA sequences in the constructs. This might be due to 
contamination of samples in the molecular cloning process. Therefore, we were not 
able to proceed to the next step where we would insert the BPLF1 gene. Further work 
is required to generate tools to screen T cell responses to EBV structural proteins that 
are independent of HLA-type.  
 
SUMMARY, CONSIDERATIONS AND FUTURE WORK: 
In this project only nine donors were screened for T cell responses therefore, to 
validate these preliminary findings a larger number of healthy EBV-seropositive people 
should be screened for T cell responses to EBV structural proteins. Also to confirm that 
MCP and LTP can only be detected in EBV-seropositive people EBV-seronegative 
people should be screened for T cell responses to MCP and LTP even though, it is 
suggested that T cell responses to the LTP cannot be detected in EBV-seronegative 
people (Schmaus et al., 2004). Furthermore, people with IM and EBV malignant 
tumours should be screened for MCP and LTP to examine whether they exhibit 
impaired immunity. If this is the case, and the MCP and LTP are shown to be efficacious 
vaccine candidates, then a vaccine would be particularly warranted in these 
individuals. 
 
The prediction of T cell epitopes method used in cellular biology part of this project is 
not the only strategy for screening T cell responses. Screening using a whole antigen 
approach is also desirable as it is not dependent on HLA-type. Unfortunately, this was 
not achieved in the current project. Using T cell epitopes that were predicted to be 
HLA-A*02 or HLA-B*07 restricted should in theory only elicit responses in HLA-A*02 or 
HLA-B*07 donors. Nevertheless, donor 3 included in our project was HLA-A*03 and 11 
and HLA-B*15 and 35 and exhibited T cell responses to the predicted T cell epitopes 
from both MCP and LTP. Thus, despite using a combination of three online prediction 
algorithms, and only selecting peptides that concurred, predictions are clearly only an 
estimate, and generate T cell epitopes of other specificities. However, using a T cell 
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epitope prediction algorithm is a more informed way of dissecting a protein randomly, 
and is more cost effective than buying overlapping peptides.  
   
In addition to circumventing the methodological limitations of this project (e.g., 
attempting different T cell cloning techniques, and persevering with the molecular 
biology), further experiments should be conducted to validate preliminary results 
presented in this thesis. The result would be to expand the knowledge of T cell 
responses to the MCP and LTP. The first experiment could include successful 
establishment of T cell clones specific for LTP. Furthermore, experiments to identify 
minimal T cell epitopes for both the MCP and LTP would have to be conducted. This 
could be achieved by systematically shortening the sequence of stimulating T cell 
epitopes from 20mers down to 9mers, screening T cell clones for IFN-γ production. It 
was shown in this thesis that CD4+ T cell clones specific for the MCP recognise lytic 
LCLs. It was shown in this thesis that CD4+ T cell clones specific for the MCP recognise 
lytic LCLs. A consideration is what the source of the antigen was and its route of 
presentation to the T cell. For example, it is currently unknown whether CD4+ T cells 
are directly recognising endogenously processed and presented antigen by the lytic 
LCL, or whether this antigen is derived from viral particles released from other lytic 
cells which have then bound to neighbouring LCLs with epitopes being processed and 
presented from the abundant virion protein to the T cells. This could be addressed by 
an experiment that would require a full HLA-restriction of the CD4+ T cell clones. In the 
experiment to explain the source of antigen, CD4+ T cell clones would be incubated 
with two different panels of LCLs at the same time. First, HLA-mismatched LCLs 
expressing a full panel of EBV proteins would be added to T cells, and, as with all LCLs, 
a number of these cells would be in lytic cycle, the proportion of which could be shown 
by BZLF1 or VCA staining and flow cytometry. Second, BZLF1 knock out LCLs with the 
HLA-type matched to the CD4+ T cell clones would also be added. IFN-y produced by 
CD4+ T cell clones would indicate that antigens and/or virus are being released from 
the lytic LCLs (which would not be recognised by the clones) but would be taken up 
and processed by the latent BZLF1 knock out LCLs. In turn, antigen presented to clones 
by the BZLF1 LCLs would be recognised due to matched HLA-typing. As the BZLF1 
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knock out LCLs cannot enter lytic cycle, the presentation of BcLF1 epitopes could only 
be a result of virions/antigen being released from the mismatched LCLs. This 
experiment would clarify whether cell/cell contact would be needed or antigen could 
be recognised directly by the CD4+ T cell clones.   
 
Irrespective of the source of antigen, the above result and discussion implies that CD4+ 
T cells may recognise newly infected B cells. Along with examining a similar effect in 
CD8+ T cells, it would be of importance to examine how quickly after infection, the 
MCP and LTP proteins are expressed, and how quickly a T cell response can be 
detected. If MCP or LTP-specific T cells recognise (and kill) B cells very early in the 
infective cycle (i.e., within 24 hours) then it might be that these EBV structural proteins 
are good vaccine targets. To further investigate MCP and LTP specific T cell responses, 
killing assays could be performed to inspect whether T cell clones destroy their targets. 
For a prophylactic vaccine to be successful, it would need to generate long lasting T cell 
immunity that both recognises and eliminates infected cells.  
 
CONCLUSION: 
The results of this thesis show that healthy people exhibit frequent CD4+ and CD8+ T 
cell responses to two EBV structural proteins, the MCP and LTP. The results of this 
thesis imply that the MCP and LTP are expressed in healthy EBV-seropositive people. 
The most important finding in this project is that CD4+ T cell clones specific for the 
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The leading cause of death in developed countries is attributed to cancer thus, cancer 
is becoming a major health problem worldwide as in 2008 there were 12.7 million new 
cases and 7.6 million people died of cancer worldwide. Therefore, the progress in 
treatment options is of crucial importance as even in the 21st century cancer treatment 
is still challenging.  
The overall progress of medicine has opened new possibilities of potential advanced 
therapies and one of them is the epigenetic therapy involving the treatment with 
HDAC inhibitors such as valproic acid (VPA). In order to any new chemotherapeutic 
agent becomes available for treatment the effects have to be characterized and 
responses of normal and cancer cells have to be assessed.  
In our project we have utilized microarray analysis to examine transcriptional response 
in lymphoblastoid cell line (LCLs) and Burkitt lymphoma cells (BLs). Our results showed 
an increased histone acetylation levels in treated cells and changes in cell cycle with 
cell cycle arrest in LCLs and BLs. Additionally, in some BLs substantial apoptosis was 
observed. In LCLs we also observed morphological changes in treated groups. When 
performing gene ontology (GO) analysis we saw enrichment in GO terms cell cycle in 
LCLs whereas, in BLs GO terms related to small cell lung cancer, prostate cancer and 
p53 signalling pathway were enriched. This results suggest that VPA may be affecting 
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Cancer has become a leading cause of death in developed countries whereas, in 
developing countries it is the second leading cause of death (Jemal et al., 2011). Even 
in the 21st century, with remarkable progress in molecular and cellular biology, cancer 
treatment is still challenging. In general the treatment consists of chemotherapy, 
immunotherapy, hormonal therapy, radiation therapy and surgery (Baskar et al., 
2012). However, in pursuance for a new strategies for cancer treatment epigenetic 
therapy emerged (Mai and Altucci, 2009), as epigenetic defects were found in many 
diseases and the majority of them were cancers (Nakao, 2001). Epigenetic defects, 
such as redistribution of histone modifications (Ghai et al., 2013), can occur due to 
changes in the epigenome promoting transcriptional repression of tumour suppressor 
genes causing tumourigenesis and cancer progression (Carew et al., 2008). Therefore, 
epigenetic therapy which corrects epigenetic defects shows a promising potential 
towards advanced cancer treatment (Peedicayil, 2006). Acetylation is one of many 
histone modifications and is regulated by histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). HDACs are transcriptional repressors and can repress 
tumour suppressor genes promoting tumour initiation. However, histone deacetylases 
inhibitors (HDACi) can restore normal expression levels of tumour suppression genes 
suppressed by HDACs (Bannister and Kouzarides, 2011). This project examined 
transcriptional response to HDACi treatment with valproic acid (VPA) in normal and 
cancer cell lines. The results of this project provide new insight in potential new 




Epigenetics is a specific field of genetics and the word itself actually means “outside 
conventional genetics” (Jaenisch and Bird, 2003). In the middle of the 20th century 
genetic code was discovered and it was thought that genetic information is passed 
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from one cell to another with no changes except if mutations occur. It was elucidated 
decades later that there is another code termed the epigenetic code which can be 
altered depending on epigenetic marks but is heritable through cell proliferation 
(Huidobro et al., 2013). Epigenetics refers to the control of gene expression and cell 
phenotype without altering genomic DNA sequence (Bachmann and Bergmann, 2012, 
Tang et al., 2013, Ngalamika et al., 2012, Weitzman, 2012, Huidobro et al., 2013) by 
chromatin remodelling such as DNA methylation, histone modifications (e.g. 
methylation and acetylation of the histones) and non-coding RNAs (Bachmann and 




In every cell of the human body there is 2 meters of DNA encoding approximately 
23,000 protein-coding genes (Roopra et al., 2012) which are the template of our 
heredity (Jenuwein and Allis, 2001). 3x109 bases of DNA needs to be packed into the 
nucleus in such a way as to be accessible for gene transcription replication and repair 
processes when necessary. Therefore, DNA is wrapped around basic proteins termed 
histones in a highly organised manner. The DNA -histones complex is called chromatin 
(Jenuwein and Allis, 2001, Roopra et al., 2012). Chromatin was first described 130 
years ago (Hübner et al., 2013) and abnormal chromatin in cancer cell in 1914 by 
Theodor Boveri (Boveri, 1914). However, the true modern description of chromatin 
appeared in 1920 by Heitz (Heitz, 1929).  
Chromatin plays a crucial role in regulation of gene expression as packaging of DNA 
regulates the genes accessibility (euchromatin) or inaccessibility (heterochromatin) to 
transcription (Hübner et al., 2013). The basic unit of chromatin is the nucleosome 
(Jiang and Pugh, 2009, Zentner and Henikoff, 2013), consisting of DNA wrapped around 
histones with linker DNA (Jenuwein and Allis, 2001, Hübner et al., 2013, Roopra et al., 
2012, Inche and La Thangue, 2006, Tóth et al., 2013), which are 10 - 80 bp apart 
forming a 10 nm fibre termed “beads on a string”. When compacted even tighter the 
10 nm fibre forms a higher order helical fibre 30nm in diameter with 6 - 11 
Bajt T. Analysing the transcriptional response to histone deacetylase inhibitors treatment in normal and 
cancer cell lines. MRes thesis, University of Birmingham, 2013.  




nucleosomes per turn. 30 nm fibres have been so far only identified in-vitro but there 
is no clear evidence of 30 nm fibres in-vivo. These fibres are further condensed by 
addition of scaffold proteins into even higher order fibres in interphase and into 200 - 
300 nm chromonema structure in mitotic chromosomes. Depending on the position in 
nucleus, the differentiation stage of the cell, the cell cycle etc. chromatin changes in 
structure (figure 1) (Hübner et al., 2013).  
 
 
Figure 1: Chromatin structure and packaging. DNA double helix wraps around histones forming histone 
– DNA complex termed nucleosome which forms a higher order complex termed chromatosome with 
histone H1. This structure is termed “beads on a string” and is 10 nm in diameter. With further 
compaction 30 nm fibre is formed and with increased levels of compaction fibre is compacted into 




Position of nucleosomes on the genome is not random (Bai and Morozov, 2010) as 
proven with new advanced technologies which allowed nucleosome maps of some 
species, including human (Jiang and Pugh, 2009). Nucleosomes consist of 146 bp DNA 
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wrapped around an octamer of core histone proteins (an H3-H4 tetramer and two 
copies of H2A-H2B dimer) with linker histone protein H1 in 1.65 negatively supercoiled 








Figure 2: Nucleosome structure. Structure of the nucleosome obtained by x-ray crystallography showing 
histones (light grey) with DNA (dark grey with dark pink) and lysine residues between DNA and the 
histones (blue) (front and side view)  (Jiang and Pugh, 2009). 
 
Nucleosomes regulate accessibility of genes to transcriptional machinery (Roopra et 
al., 2012) and nucleosome maps revealed that 90% of promoters have a low number of 
nucleosomes. Those regions are termed nucleosome-depleted regions (NDR) (Bai and 
Morozov, 2010) or nucleosome-free regions (NFR) (Jiang and Pugh, 2009). Regulation is 
accomplished in several distinct ways, through replacement of core histones and 
repositioning or eviction of histones from DNA (Zentner and Henikoff, 2013). 
 
1.4.1. Nucleosome positioning and transcription regulation 
 
There are a few mechanisms by which nucleosome positioning regulates transcription 
of protein-coding genes in genome. Firstly, promoters are usually located in NDR which 
allows free binding of transcription factors to the promoter and consequently 
nucleosomes on both sides of the promoter are evicted, exposing all functional sites, 
thus allowing gene transcription. Secondly, nucleosomes can occupy activator binding 
sites. After the attachment of nucleosome remodelling enzymes, binding of 
transcription activators on the activator is enabled. The nucleosomes get evicted and 
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transcription can begin. Genes can nevertheless still be repressed suggesting there are 
other repressor mechanisms in place. Thirdly, when a promoter is in the NDR bound to 
the activator, neighbouring nucleosomes are evicted to allow transcription but return 
to their position to repress transcription. This is a cyclic process. Fourthly, in the case 
of two promoters regulating one gene, the first promoter, located in the NDR, is 
activated causing eviction of neighbouring nucleosomes where the second promoter is 
located. Activation of the second promoter promotes further depletion of 
nucleosomes and activation of protein-coding gene (Bai and Morozov, 2010). 
 
1.4.2. Nucleosomes and DNA access 
 
Another way of controlling gene transcription is by controlling the accessibility of 
transcription machinery to the DNA being wrapped on nucleosomes. There are three 
mechanisms; the first mechanism involves nucleosome sliding exposing the target 
gene to transcription machinery. The second mechanism requires ATP-dependent 
chromatin remodelling complexes (e.g. SWI/SNF) which exploit ATP from hydrolysis 
and binds to DNA forming DNA loops. The third mechanism involves nucleosome 
eviction for successful transcription by anti-silencing function 1 (Asf1) and specific 
chaperone (Chz1) (Jiang and Pugh, 2009) (figure 3). 
 
Figure 3: Mechanisms for transcriptional regulation. A) A non-modified, stable nucleosome where gene 
in red can be only accessible by nucleosome sliding indicated with arrows. B) Nucleosome with 
remodelling enzymes creating DNA loops, gene in blue can become accessible. C) Nucleosome eviction is 
sometimes necessary for transcriptional machinery to be able to bind to the DNA (Jiang and Pugh, 
2009). 
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1.5. Histone modifications  
 
There is another mechanism by which nucleosome properties can be altered – histone 
modifications (Zentner and Henikoff, 2013). The histones as part of the nucleosomes 
have N-terminal tails sticking out from the nucleosomes which are prone to 
posttranslational modifications. Methylation and acetylation (Roopra et al., 2012) are 
the most frequent histone modifications (Nightingale et al., 2006).    
 
Genetic code describes information in the genome whereas the histone code extends 
the information of the genetic (DNA) code with additional information of existing 
protein interactions within the epigenome (Jenuwein and Allis, 2001). The hypothesis 
that histone tails with modification marks provide binding sites for effector proteins 
was first suggested by Turner et al. in 1992 (Turner et al., 1992, Turner, 1993). The 
bromodomain, for example, recognises modification marks for acetylation activating 
transcription and chromodomains recognise modification marks for methylation 
repressing transcription (Inche and La Thangue, 2006). 
 
There are over 100 distinct modifications described and the list is still increasing. The 
most studied histone modifications are methylation and acetylation (Zentner and 




Histone methylation was discovered 40 years ago by Murray (Murray, 1964). It can 
occurs as methylation of H3 and H4 histones with mono-, di-, and trimethyl groups per 
residue when methylation occurs on lysine residues (Kumar et al., 2012). However, it 
occurs as mono- and dimethyl groups per residue when methylation occurs on arginine 
residues (Zentner and Henikoff, 2013). The SET domain starts methylation on lysine 
residues; however, methylation on arginine residues starts by co-activator arginine 
methyltransferase (CARM1) and protein arginine methyl transferase (PRMT1) (Kumar 
et al., 2012).  
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1.5.2. Acetylation  
 
Acetylation was the first described histone modification, discovered in 1961 (Phillips, 
1963). Acetylation of lysine residues is regulated by histone acetyltransferases (HATs) 
and histone deacetylases (HDACs) (Bannister and Kouzarides, 2011, Zentner and 
Henikoff, 2013).  
 
HATs neutralize positive charge between DNA and lysine residues by addition of acetyl 
group from acetyl CoA to the side chain of the lysine residue (Bannister and 
Kouzarides, 2011) on the N-terminal tail of the histone (Sterner and Berger, 2000). The 
histone – DNA connection or nucleosome - nucleosome interactions weaken due to 
neutralization of the lysine residue causing chromatin to become loose around the 
nucleosome. Transcription is therefore increased due to higher accessibility of the 
transcription machinery to the DNA (Inche and La Thangue, 2006, Sterner and Berger, 
2000). There are two types of HATs. Type A HATs acetylate N-terminal tails of histones 
with three families GNAT, MYST and CBP/p300. Type B HATs acetylate only free 
histones in the cytoplasm (Bannister and Kouzarides, 2011).  
 
HDACs have the opposite effect on transcription as HATs, as they have deacetylation 
effects, restoring the positive charge of lysine residues on histones (Bannister and 
Kouzarides, 2011) by removing the acetyl groups from the histones (Kumar et al., 
2012). Therefore, they are predominantly transcriptional repressors. There are several 
classes of HDACs; class I, II a/b, III and IV (Bannister and Kouzarides, 2011). Class I 
(HDAC 1, 2, 3 and 8), class II a/b (HDAC 4, 5, 6, 7, 9 and 10) and class IV (HDAC 11) are 
zinc dependent HDACs whereas, class III (SIRT 1, 2, 3, 4, 5, 6 and 7) are NAD+ 
dependent HDACs (Carew et al., 2008, Glaser, 2007, Cortez and Jones, 2008). 
Observations have shown overexpression and/or misregulation of HDACs in cancer 
cells without HDAC genes being mutated (Inche and La Thangue, 2006). Changes in the 
genome are not reversible however, changes in the epigenome are, and can be 
achieved by use of “epigenetic drugs” such as HDAC inhibitors (Bannister and 
Kouzarides, 2011, Tang et al., 2013).  
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1.6. HDAC inhibitors 
 
One of the important hallmarks of cancer are the changes in the epigenome which 
promote transcriptional repression of tumour suppressor genes causing increased 
tumorigenesis and cancer progression. Repression of tumour suppressor genes is 
evident in many types of cancer such as colon cancer, prostate cancer, breast cancer 
etc. (Carew et al., 2008). Therefore, HDAC inhibitors (HDACi) are important anti-cancer 
targets (Inche and La Thangue, 2006) as they induce inhibition of cancer cells, promote 
apoptosis and induce differentiation (Bannister and Kouzarides, 2011), thus, offering a 
promising target for pharmacological inhibition of cancer (Carew et al., 2008).   
 
HDACi were developed to alter epigenetic changes and restore normal expression 
levels of tumour suppression genes. These HDACi are short-chain fatty acids (valproic 
acid (VPA) and butyrate), hydroxamic acids (suberoylanilide hydroxamine acid (SAHA), 
Trichostatin-A (TSA), LBH589, PXD101 and tubacin), benzamides (MS-278) and cyclic 
tetrapeptides (depsipeptide) which are not target specific but do inhibit only specific 
classes of HDACs (figure 4). HDACi increase distance between the nucleosome and the 
DNA allowing higher accessibility to DNA, resulting in increased transcription (Tang et 
al., 2013). Furthermore, HDACi induce apoptosis through the extrinsic pathway of 
apoptosis by increased expression of death ligand TRAIL which starts apoptosis only in 
transformed cells but not in normal cells (Carew et al., 2008). For example, the HDACi 
SAHA can be almost 1000-fold more toxic for malignant T-cells in comparison to non-
malignant T-cells (Zhang et al., 2005). Additionally, HDACi affect apoptosis also through 
the intrinsic pathway of apoptosis by down-regulating pro-apoptotic genes and up-
regulating anti-apoptotic genes. Therefore, cancer cells undergo apoptosis. 
Furthermore, HDACi inhibit angiogenesis, which is of a high importance for tumour 
formation and metastases development, by decreasing pro-angiogenic factors (e.g. 
vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF1α). 
Moreover, HDACi not only affect histone modifications and restore normal expression 
levels in tumour suppressor genes but also affect non-histone proteins (e.g. p53, Rb, 
tubulin, E2F1) (Carew et al., 2008, Marks and Xu, 2009).  
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1.7. HDACi as chemotherapeutics 
 
Anti-cancer properties of the HDACi are already used in clinical trials to potentially 
obtain new HDACi chemotherapeutics. SAHA has already been approved by Food and 
Drug Administration (FDA) for treatment of cutaneous T-cell lymphoma (Carew et al., 
2008, Cortez and Jones, 2008), following approval of Depsipeptide (Romidepsin) 
(Marks and Xu, 2009). Also in phase I is LBH589 and in phase II are PXD101, butyrate, 
depsipeptide and MS-275 (Carew et al., 2008).  Whereas, VPA is in phase III (Marks and 
Xu, 2009) (figure 5).  
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Figure 4: HDACi with target HDACs. Different HDAC inhibitors target different classes of HDACs (Carew 
et al., 2008). 
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Figure 5: Clinical status of HDACi (Carew et al., 2008, Marks and Xu, 2009). 
 
HDACi as chemotherapeutics can be administrated in many combinations such as two 
epigenetic drugs together, epigenetic drug and conventional chemotherapeutic (Cortez 
and Jones, 2008), epigenetic drug and new targeted agents or epigenetic drug in 
combination with radiation treatment. Data suggest a good correlation between 
epigenetic drugs and gemcitabine, paclitaxel, cisplatin, etoposide and doxorubicin as 
HDACi promote apoptosis, enabling higher potency of conventional 
chemotherapeutics (Carew et al., 2008). HDACi also increase sensitivity of cancer cells 
to conventional chemotherapeutics when chemotherapy resistance occurs (e.g. 
cisplatin resistance) as HDACi allow better interactions between chemotherapeutic 
and DNA by chromatin loosening. Furthermore, HDACi can be used in treatment of 
solid tumour as in hematologic malignancies (Cortez and Jones, 2008). According to 
the service of the U.S. National Institutes of Health termed Clinical Trials there are 355 
clinical trials worldwide investigating HDACi as chemotherapeutics. The majority of 
clinical trials are in the USA (251 clinical trials) (figure 6) and Europe is second (49 
clinical trials) (figure 7). The most studies focuses on acute myelocytic leukemia (AML) 
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Figure 6: HDACi clinical trials worldwide in 2013. There are 355 clinical trials investigating HDACi as 















Figure 7: HDACi clinical trials in Europe in 2013. There are 49 clinical trials in Europe investigating HDACi 
as chemotherapeutics (ClinicalTrials.gov, 2013). 
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SAHA is the first HDACi being approved by FDA for treatment of CTCL and is in phase II 
of clinical trials for solid tumours (Cortez and Jones, 2008) and in phase I-III clinical 
trials in combination with other chemotherapeutic drugs such as tamoxifen, 
bortezomib, oxaliplatin, carboplatin/paclitaxel etc. (Glaser, 2007). It is also known by 
the names Vorinostat and Zolinza™. It reacts as zinc chelator and binds in catalytic 
domain and inhibits HDACs class I and II (figure 5) (Mann et al., 2007, Cortez and Jones, 
2008). SAHA is a small molecule with IUPAC formula C14H20N2O3 and molecular weight 
264.32g/mol (Duvic and Vu, 2007). The drug is available as oral drug in 100 mg 
capsules. It has been proven when administrated in combination with other 
chemotherapeutic drugs SAHA has additive or synergetic effect. It has low toxicity but 










VPA is an antiepileptic drug and mood stabilizer (Bialer, 2012, Blaheta et al., 2005) 
synthesised by Burton in 1882 (Chateauvieux et al., 2010). The anti-cancer effects such 
as inhibited proliferation, induced differentiation and decreased apoptosis (Cortez and 
Jones, 2008) were first observed in 1997 (Blaheta et al., 2005). VPA is well tolerated in 
adults and stable (Cortez and Jones, 2008) with half life time of 9 to 16 hours. 
However, it can provoke side effects presenting as prolonged sleep duration in young 
patients, dermatological side effects, decreased fertility, neurological side effects etc. 
It inhibits HDACs classes I and II (figure 5) by increased acetylation (Nightingale et al., 
2007), increasing transcriptional responses and increased DNA repair (Marks and Xu, 
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2009). As an antiepileptic drug it is available in many forms such as tablets, syrup and 
local injections (Chateauvieux et al., 2010). At the moment there are 22 studies 







Figure 9: Valproic acid structure (Chateauvieux et al., 2010). 
 
1.8. Summary, overview and aims of this thesis. 
 
The aim of this project was to analyse the transcriptional response to histone 
deacetylase inhibitors treatment in normal and cancer cell lines. Whereas the 
properties of VPA as antiepileptic drug and mood stabilizer (Bialer, 2012, Blaheta et al., 
2005) are well studied the anti-cancer effects and means of action are less understood 
despite that the increased acetylation (Nightingale et al., 2007), increasing 
transcriptional responses and increased DNA repair (Marks and Xu, 2009) have been 
observed. Our group has previously shown that lymphoblastoid cells show a limited 
short-term transcriptional response to VPA treatment that appears to protect them 
from aberrant histone modification and apoptotic effects. Therefore, the questions to 
address were: 
1. How do non-malignant lymphoblastoid cells adapt to long-term exposure to 
VPA? 
2. How do malignant Burkitts lymphoma cells respond to VPA treatment? 
3. How do short-term transcriptional changes in Burkitts cells relate to their VPA 
response? 
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Reagent in text Formulation 
10 x SDS loading buffer 1 M Tris pH 8, 10 mM EDTA, 10% SDS, 1.432 M β-
mercaptoethanol, 0.1 g bromphenol blue 
LCLs media RPMI 1600 (Sigma Life sciences, USA), 10% main batch FBS 
(Sigma Life sciences, USA), 1% streptomycin and penicillin 
(Invitrogen), 1% L-glutamine 
BL media RPMI 1600, 10% main batch FBS, 1% streptomycin and 
penicillin, 1% L-glutamine, 1mM Hepes Buffer, Pyrovate 
1:100, magic mix 1:100 
Blocking solution 5% non-fat dry milk (Chivers, Ireland), TBS-T  
Magic mix BCS 10 mM, 10 x PBS, α-thioglycerol, u.p.H2O 
Propidium Iodide (PI) 
Staining Buffer 
FACS buffer (PBS, 5% FBS, 0.02% NaN3), 1mg/ml Propidium 
Iodide, 10mg/ml RNase A, 10% NP40 and 1mg/ml tri-sodium 
citrate   
TEB  10% Triton x 100 (Sigma Life sciences, USA), 0.1M PMSF, 2% 
Sodium Azide, 10xPBS, ultra pure water 
LCLs freezing mix 78% RPMI 1600, 10% main batch FBS, 1% streptomycin and 
penicillin, 1% L-glutamine, 10% DMSO 
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Other reagents Source 
QIAquick PCR Purification Kit  QIAGEN, Sussex, UK 
QIAquick RNeasy Mini Kit QIAGEN, Sussex, UK 
cDNA Synthesis System Kit  Roche, UK 
Coomassie reagent Thermo Scientific, USA 
Gene expression array analysis kit  NimbleGen, UK 
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2.2.1. 7 day exposure of LCLs to sodium valproate (VPA) 
 
LCL responses to exposure to sodium valproate (VPA) were measured at four time 
points (day 1, 3, 5 and 7) and at three experimental conditions (untreated control 
group, 0.5 mM VPA and 1 mM VPA) to establish appropriate time points and 
concentration of VPA for further experiments. Every second day half of the culture 
media with VPA was removed and replaced by fresh media or fresh media with 0.5 or 1 
mM VPA to ensure stable concentration of VPA for the duration of the experiment. At 
each time point photos were taken to observe potential morphological changes. All 
together there were twelve groups with different experimental conditions. At each 
time point cells were collected for Fluorescence-activated cell sorting (FACS) analysis 
and Western Blotting analysis. Cells were collected from in-vitro culture and 
centrifuged at 350 x g for 5 min at 4°C. Pellets were re-suspended in PBS with sodium 
butyrate and cells were counted. Cells were collected (1x106) for FACS analysis and 
centrifuged at 1500 min x g for 5 min at 4°C. Pellets were re-suspended in 70% ethanol 
and stored at -20°C. The remaining cells were centrifuged at 350 x g for 5 min at 4°C. 
Pellets were loosened and stored at -80°C for acid extraction of the histones.  
Figure 10: Timeline of experiment with 7 day long exposure of LCLs to VPA. LCLs in culture were 
exposed to VPA for 7 days. Fresh media or fresh media with VPA at different concentrations (0.5 and 1 
mM VPA) was replaced every second day and photos were taken to observe potential morphological 
changes. At each time point (day 1, 3, 5 and 7) cells were collected for FACS analysis and Western 
Blotting analysis.   
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2.2.2. 14 day exposure of LCLs to 0.5 mM sodium valproate (VPA) 
 
To evaluate long-term effects of VPA on global gene expression an experiment was 
conducted treating LCLs with 0.5 mM VPA for 14 days. Cells were collected at four time 
points (day 1, 4, 7 and 14). Every second day half of the culture media was removed 
and replaced by fresh media or fresh media with 0.5 mM VPA to ensure stable 
concentration of VPA for the duration of the experiment. Photos were taken before 
adding the fresh media every second day to observe potential morphological changes. 
There were three biological replicates (groups A, B and C) for RNA analysis alongside a 
fourth group for Western Blotting analysis (group W). At each time point cells were 
collected for Western Blotting analysis from group W. Cells from groups A, B and C 
were collected for FACS analysis and Microarray analysis. Cells for Western Blotting 
and FACS were collected as described in section 2.2.1. Cells for Microarray analysis 
were collected from in-vitro culture and centrifuged at 350 x g for 5 min at 4°C. Pellets 
were loosened and stored at -80°C for further RNA purification.  
 
Figure 11: Timeline of experiment with 14 day long exposure of LCLs to 0.5 mM VPA. LCLs in culture 
were exposed to VPA for 14 days. Fresh media or fresh media with 0.5 mM VPA was replaced every 
second day and photos were taken to observe potential morphological changes. At each time point (day 
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2.2.3. 24 hour exposure of BLs to VPA  
 
Three Burkitt lymphoma cell lines (BLs) 30, 31 and 41 were exposed to different VPA 
concentrations (5mM, 1mM, 0.5mM and 0.2mM) to observe cell cycle responses of 
cells 24 h post-treatment. BLs were seeded into 6 well plates and treated with VPA. 
After 24 h cells were collected for further FACS analysis and prepared as described in 
section 2.2.1. 
 
2.2.4. Cell density of BLs in culture versus VPA treatment 
 
BLs 30, 31 and 41 were seeded into 6 well plates at 1x106, 3x106 and 5x106 and treated 
with VPA at concentrations of 0.5 mM and 5 mM with untreated control group. After 
24 hour exposure to VPA BLs were collected for further FACS analysis and prepared as 
described in section 2.2.1.  
 
2.2.5. BLs exposure to 1mM VPA 
 
To evaluate effects of VPA on global gene expression in BL cell lines, an experiment 
was conducted treating BL cell lines 30, 31 and 41 for 30 min, 60 min and 120 min with 
1 mM VPA alongside untreated control group. BLs were seeded at 1x106 cells/ml. 
There were three biological replicates for each BL cell line (groups A, B and C) for RNA 
analysis alongside fourth group for Western Blotting analysis (group W). At each time 
point cells were collected for Western Blotting analysis from groups W. Cells from 
groups A, B and C were collected for Microarray analysis. Cells for Western Blotting 
were collected as described in section 2.2.1. Cells for Microarray analysis were 
collected from in-vitro culture and centrifuged at 350 x g for 5 min at 4°C. Pellets were 
loosened and stored at -80°C for further RNA purification. 
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Figure 12: Timeline of the experiment treating BLs with 1mM VPA for 30 min, 60 min and 120 min. BLs 
were treated and collected for Western Blotting and Micro array analysis 30, 60 and 120 min after 
treatment. BLs were collected for Western Blotting analysis and Microarray analysis. 
 
2.2.6. Fluorescence-activated cell sorting (FACS) analysis 
 
Collected cells re-suspended in 70% ethanol for FACS analysis were centrifuged at 350 
x g for 5 min and washed twice in ice-cold PBS. Samples were re-suspended in 
Propidium Iodide (PI) Staining Buffer and incubated for 30 min at room temperature 
covered with tinfoil to exclude light. Samples were filtered through cell filters into 
polypropylene FACS tubes and analysed on the flow cytometer gated on the forward 
versus side-scatter. Data was analysed using Summit V.3. 
 
2.2.7. Acid extraction of histones 
 
Cell pellets were re-suspended in TEB buffer at concentration of 1x107 cells/ml and 
incubated on ice for 10 min. Cells were washed by centrifuging at 900 x g for 10 min at 
4°C. Supernatant was removed and cell pellets were re-suspended in half of the 
volume of TEB buffer and centrifuged at 900 x g for 10 min at 4°C. The supernatant 
was removed and cell pellets were re-suspended in 0.4N HCl at concentration of 4x107 
cells/ml. Cells were incubated overnight at 4°C. Cells were washed by centrifuging at 
900 x g for 10 min at 4°C. Supernatant containing histones was removed to perform 
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2.2.8. Coomassie Protein Assay 
 
By dissolving bovine serum albumin (BSA) in u.p.H2O, standards were prepared at 
concentration of 5.0, 1.0, 0.5, 0.25, 0.125, 0.0625mg/ml. Coomassie reagent was 
added (1 ml) to each cuvette following by 10 µl of each standard and samples 
containing histone extractions. Blank was produced by adding 10 µl u.p.H2O to cuvette. 
Cuvettes were incubated for 5 min at room temperature and read at 595nm 
(GeneFlow Implen P300 Reader) blanking against the u.p.H2O to obtain absorbance 
values for determination of histone concentrations. 
 
2.2.9. Western Blotting assay 
 
After each time course global acetylation levels in treated cells relative to controls was 
assayed by Western Blotting. Lower gel (15% acrylamide, 0.5% bisacrylamide, 0.375M 
TRIS, pH 8.8, 0.1% SDS, 0.03% APS, 0.1% TEMED) was poured into gel cassette and left 
to set. Isopropanol was layed on top for easier inspection of gel setting and was 
poured off before upper gel was poured into the gel cassette. Upper gel (3% 
acrylamide, 0.16% bisacrylamide, 0.125M TRIS, pH 6.8, 0.03 SDS, 0.03 APS, 0.1% 
TEMED). Samples containing histones were mixed in eppendorf tubes with 50% 
glycerol, 10xSDS loading buffer and u.p.H2O and incubated for 10 min at 99°C and then 
placed on ice for 5 min. Meanwhile, reservoir buffer was prepared which consisted of 
0.1% SDS, 50mM TRIS and 380mM glycine. Gel cassettes were transferred into tank 
and reservoir buffer was poured into the tank. Prepared samples were loaded onto the 
gels. Gels were run for 3h at 20W, 60-80mA. SDS transfer buffer consisting of 25mM 
TRIS, 192mM glycine, 20% methanol and u.p.H2O was prepared. For protein transfer, 
transfer cassettes were assembled placing gels onto the membrane, sponges and filter 
papers. Transfer cassettes were placed into transfer tank and top up with buffer. 
Blotting process was run for 3h at 160V, 300 mA. Transfer cassettes were disassembled 
and membranes were incubated for 5 min in Ponceau S dye (Sigma, UK) to check for 
effective transfer and equal loading of the proteins (histones) and rinsed with dH2O. 
Membranes were blocked in blocking solution at room temperature for 1h and placed 
onto a rocking platform (Stuart rocker, SSL4). Membranes were probed with H3/H4 
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primary antibody pairs (first pair: H4K5ac (R41) & H3K9ac (R607); second pair: 
H4K16ac (R252) & H3K4me3 (R612)) and membranes were incubated at room 
temperature for 1h placed on the rocking platform. Membranes were washed in TBS-T 
for 10 min three times placed on the rocking platform. Secondary antibody Licor was 
added and membranes were incubated at room temperature for 1h placed on the 
rocking platform. Membranes were washed in TBS-T for 10 min three times placed on 
the rocking platform and scanned using LI-COR Odyssey Infrared Imaging System 
scanner and incubated overnight at 4°C in TBS-T placed on the rocking platform.  
 
After overnight washing in TBS-T membranes were incubated in primary antibody H3 
C-terminus (AB-1791) at room temperature for 1h placed on the rocking platform and 
washed in TBS-T for 10 min three times placed on the rocking platform. Second Rabbit 
IgG antibody (Rockland 611-131-122) was added and membranes were incubated at 
room temperature for 1h placed on the rocking platform and washed in TBS-T for 10 
min three times placed on the rocking platform. Membranes were scanned using LI-
COR Odyssey Infrared Imaging System scanner.     
 
2.2.10. Thawing cells 
 
Cells were thawed in a 37°C water bath and slowly re-suspended in RPMI media (LCLs 
media or BL media) using the drip-by-drip method. Cells were washed in RPMI media 
at 350 x g for 5 min. Cells were re-suspended in RPMI media and transferred into 
culturing flasks. 
 
2.2.11. Freezing cells 
 
Cells in RPMI media were centrifuged at 350 x g for 5 min, re-suspended in LCLs or BL 
freezing mix and transferred to a cryovials. Vials were frozen at −1°C/min to −80°C 
using a freezing container (Mr Frosty, Nalgene). Cells were moved to  −196°C within 24 
hours.  
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2.2.12. RNA extraction 
 
RNA purification for Microarray analysis was performed using RNeasy Mini Kit (Qiagen, 
UK). Collected cells in pellet were thawed at room temperature and Buffer RLT was 
added. Homogenization of the samples was performed using needle and syringe. One 
volume of 70% ethanol was added and mixed by pipetting. Samples were transferred 
onto RNeasy Mini spin columns placed onto 2 ml collection tubes and centrifuged at 
8000 x g for 15 sec. Flow-through was discarded and Buffer RW1 was added onto the 
columns. The columns were centrifuged at 8000 x g for 15 sec and flow-through was 
discarded. DNase I incubation mix containing DNase I solution and Buffer RDD was 
added onto the RNeasy columns membrane and left at room temperature for 15 min. 
Buffer RW1 was added onto the columns and columns were centrifuged at 8000 x g for 
15 sec. Flow-through was discarded.  Samples were washed twice with buffer RPE by 
centrifuging for 15 sec at 8000 x g and 2 min at 8000 x g. Flow-through was discarded. 
RNeasy spin columns were placed in centrifuge for 1 min to dry the membranes. 
RNeasy spin columns were placed into new collection tubes and RNase-free water was 
added. To elute RNA, columns were centrifuged for 1 min at 8000 x g twice. Eluted 
RNA samples were quantitated using nanodrop spectrophotometer (GeneFlow Implen 
P300 Reader) and analysed on 2% agarose gel.     
 
2.2.13. Eletrophoresis of samples 
 
Samples were electrophoresed in a 2% agarose gel in TAE for 30 - 40 min (70 - 75V) 
and visualized by GelRed dye (BioTium). Samples were mixed with loading buffer for 
visualisation before adding 10 µl onto agarose gel. 100 bp DNA Ladder marker 
(Invitrogen) was used as orientation marker of DNA separation. RNA or DNA 
separation was visualized using UV reader (BIO-RAD, Molecular Imager Gel Doc XR 
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2.2.14. Double stranded cDNA synthesis 
 
Double stranded cDNA from RNA samples was synthesized using cDNA Synthesis 
System Kit (Roche, UK). RNA samples were thawed on ice and transferred into thin-
walled PCR tubes adding oligo dT15 primer. Tubes were incubated for 10 min at 70°C 
and then immediately placed onto ice. RT-buffer, DTT, AMV, Protector RNase Inhibitor 
and dNTP-Mix were added and tubes were incubated for 60 min at 42°C. For 
terminating the reaction tubes were placed onto ice. The second strand of cDNA was 
synthesised adding 2nd strand synthesis buffer, dNTP-mix, 2nd strand enzyme blend and 
PCR water into the tubes with the samples. Samples were incubated for 2h at 16°C. T4 
DNA Polymerase was added and samples were incubated for 5 min at 16°C. Reaction 
was terminated by adding EDTA. RNA was digested by adding RNase I and digested at 
37°C for 30 min. Proteinase K was added and samples were incubated for 30 min at 
37°C. Double stranded cDNA was cleaned using QIAquick PCR Purification Kit (Qiagen, 
UK). Buffer PB was added to the samples and samples were transferred onto QIAquick 
columns and centrifuged for 60 sec. Flow-through was discarded. Buffer PE was added 
and QIAquick columns were centrifuged for 60 sec. Flow-through was discarded and 
columns were centrifuged for another 1 min. QIAquick columns were transferred into 
new 1.5 ml microcentrifuge tubes. DNA was eluted by adding Buffer EB and 
centrifuged for 1 min following by elution buffer placed directly to QIAquick columns 
membrane. Columns were incubated for 1 min at room temperature and then 
centrifuged at 8000 x g for 1 min. Double stranded cDNA samples were quantitated 
using nanodrop spectrophotometer (GeneFlow Implen P300 Reader) and stored at -
20°C.  
 
2.2.15. Microarray analysis 
 
To identify global gene expression changes Gene expression array analysis kit 
(NimbleGen, UK) was used.  
Double-stranded cDNA samples were transferred into thin-walled tubes and labelled 
by adding diluted Cy3 Random Nonamers (Cy3 Random Nonamers with Random 
Primer Buffer and β-Mercaptoethanol) and PCR Grade Water. Samples were incubated 
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for 10 min at 98°C followed by quick-chill in ice-water bath for 2 min. The 
dNTP/Klenow master mix which contained dNTP Mix (10 mM each dNTP), PCR Grade 
Water, Klenow Fragment (3’-> 5’ exo-) 50 U/µl was added to the reaction. Samples 
were incubated for 2 hours at 37°C protected from light. Reaction was stopped by 
adding the Stop Solution. Samples were transferred into new 1.5 ml microcentrifuge 
tubes containing isopropanol, mixed vigorously, incubated for 10 min at room 
temperature and centrifuged at 12,000 x g for 10 min. Supernatant was removed and 
pellets were rinsed and dislodged from tube walls by ice-cold 80% ethanol. Samples 
were centrifuged at 12,000 x g for 2 min and supernatant was removed. Samples were 
dried in a DNA vacuum concentrator (Thermo Scientific, SAVANT DNA 120 SpeedVac 
Concentrator) on low heat until dry protected from light. Samples were stored 
protected from light at -20°C overnight. Samples were spun down and pellets were 
rehydrated in PCR Grade Water and mixed vigorously for 30 sec, spun down to collect 
samples at the bottom of the microcentrifuge tubes and left on the bench to 
completely rehydrate. Samples were quantitated using nanodrop spectrophotometer 
(GeneFlow Implen P300 Reader). The 4ug labelled samples weredried in a DNA vacuum 
concentrator on low heat protected from light.  
Dried pellet samples were re-suspended in Sample Tracking Control, mixed vigorously 
and spun down to collect contents at the bottom of the microcentrifuge tubes. 
Hybridization solution was added into the tubes which consisted of 2X Hybridization 
Buffer, Hybridization Component A and Alignment Oligo. Samples were mixed 
vigorously and spun down to collect the contents and incubated for 5 min at 95°C 
protected from light. Samples were transferred and incubated at 42°C until ready for 
sample loading. The HX12 Mixer-Slides were assembled using the Precision Mixer 
Alignment Tool (PMAT). The assembled HX12 Mixer-Slides were taken out of the PMAT 
and placed onto the heat block at 42°C for 5 min and transferred into the slide bay of 
the Hybridization System (NimbleGen,UK). Samples were loaded using a Gilson 
Microman pipette and hybridized for 20 hours at 42°C. After hybridization washing 
solutions I, II and III were prepared containing ultra-pure water, 10X Wash Buffer I, II or 
III and 1M DTT solution. Wash I was heated to 42°C as Washes II and III were kept at 
room temperature. The HX12 Mixer-Slides were disassembled using Mixer Disassembly 
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Tool submerged in Wash I. Slides were rinsed for 10 – 15 sec in Wash I at 42°C and 
placed into slide rack in Wash I at room temperature and rinsed for additional 2 min. 
Slides were transferred into Wash II and washed for 1 min. Slides were transferred to 
Wash III and washed for 15 sec. Slides were removed from the slide rack and dried 
using a microarray dryer. Slides were removed from the microarray dryer and scanned 
using a NimbleGen MS 200 Microarray Scanner, UK. Data was analysed using DEVA 
software and the free online accessible programme Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 (Huang et al., 2009a, Huang et al., 
2009b).    
 
2.2.16. Single stranded cDNA for PCR validation  
 
Single stranded cDNA for PCR validation was synthesized using SuperScript™ III Reverse 
Transcriptase Kit (Invitrogen, UK). The RNA samples were transferred into thin-walled 
tubes and were incubated for 5 min at 65°C with added oligo (dT)12-18 and dNTP Mix 
and placed on ice for 1 min. The 5X First-Strand Buffer, 0.1 M DTT, RNaseOUT™ 
Recombinant RNase Inhibitor and SuperScript™ III RT were added. Samples were 
gently mixed by pipetting and incubated for 60 min at 50°C. Reaction was inactivated 
by incubating for 15 min at 70°C. 
 
2.2.17. Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (PCR) was used to validate designed gene primers for 
Microarray analysis results. Primers were designed using the free online programmes 
Primer 3 (Rozen and Skaletsky, 2000) or NCBI Primer Blast tool (Ye et al., 2012). Basic 
Local Alignment Search Tool (BLAST) (Altschul et al., 1990) was used to validate 
selected primers for selected genes. A PCR thermal cycler (MJ Research PTC 200 Peltier 
Thermal Cycler) was used and programmed with the following conditions: 95°C for 5 
min for initiation, 35 cycles of 95°C for 30 sec for denaturing, 50°C/60°C for 30 sec for 
annealing, 72°C for 30 sec/kbp for elongation. PCR products were maintained at 4°C 
and analysed on a 2% agarose gel as described in section 2.2.10. 
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3.1. LCL responses to long-term (7 days) VPA treatment 
 
To elucidate long-term effects of VPA treatment on normal cells we selected a 
lymphoblastoid cell line (LCLs) as a model for normal human cells as LCLs, though 
immortal in culture, are chromosomally stable and are widely used in genetic and 
functional studies (Tabish and Mulherkar, 2012). The experiment was conducted 
treating LCLs in culture for 7 days with 0.5 mM and 1 mM VPA. To address the question 
how VPA effects cell cycle and levels of global histone acetylation in LCLs, FACS and 
Western Blotting analysis were performed alongside observing the potential 
morphological changes by microscopy. 
 
According to cell counts at each time point (day 1, 3, 5 and 7) growth curves were 
obtained. Control cells increased in numbers and similarly, the cells growing in 0.5 mM 
VPA showed some growth. The number of cells treated with 1 mM VPA were relatively 
stable in comparison to the number of seeded cells (figure 13). FACS analysis showed a 
minimal increase in apoptosis but a significant reduction in S phase, increasing with 











Figure 13: LCLs growth curves in 7 days long experiment. LCLs were counted at every time point (day 1, 
3, 5 and 7) and growth curves were obtained. Control cells increased in numbers, whereas number of 
cells treated with 0.5 mM VPA has increased by 0.5-fold by day 7 in comparison to control cells. Number 
of cells treated with 1 mM VPA stayed relatively stable throughout the duration of the experiment. 
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Figure 14: VPA impact on LCLs cell cycle in 7 day continuous VPA treatment. LCLs FACS analysis 
example pictures presenting LCLs cell cycle of control (C) cells and after treatment with 0.5 and 1 mM 
VPA. Proportion of cells versus VPA concentration are presented. Cells labelled as Sub G0 are either 
dead or apoptotic.  
 
Western Blotting analysis was performed showing pronounced increase in acetylation 
of histones H3 and H4 after VPA treatment at day 1. The acetylation remained high 
thereafter. In untreated control cells parallel increase in acetylation was observed, for 
reasons that are not clear (figure 15).  
Figure 15: Western blotting analysis of LCLs treated for 1, 3, 5 and 7 days with 0.5 and 1 mM VPA. 
Blots present changes in histone acetylation levels of control (C) and treated cells (0.5 and 1) in histones 
H4K5ac, H3K9ac, H4K16ac, H3K4me3 and H3 C-terminal upon VPA treatment.  
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Alongside other analysis, potential morphological changes were observed by taking 
photos. Untreated control LCLs were growing in clumps and single cells were also 
observed through all 7 days of treatment. In treated LCLs there were fewer clumps and 
more single cells in culture. As treatment progressed, at both concentrations 0.5 and 1 
mM the disappearance of clumps became clear. Five days after continuous treatment 
we started to observe morphological changes as cells in the control group were round 
in shape, whereas cells in treated groups became spiky, most dramatically at 1 mM 





Figure 16: Example photos of LCLs in 7 days culture taken by light microscope.  LCLs were treated for 1, 
3, 5 and 7 days with 0.5 and 1 mM VPA. Photos were taken at 10x and 40x magnification and photos 
presented were taken from control groups and 1 mM VPA groups at day 1, 5 and 7. LCLs in control 
groups were growing in clumps with single cells however, treated LCLs were growing as single cells and 
clumps started to disappear with prolonged treatment. After 5 days of continuous treatment LCLs 
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3.2. LCL responses to long-term (14 days) 0.5 mM VPA treatment 
 
After the 7 day experiment presented in section 2.1 we established the appropriate 
VPA concentration for our next experiment in which we treated LCLs for 14 days with 
0.5 mM VPA. The aim of the experiment was to observe cell cycle changes and levels of 
global histone acetylation in LCLs by FACS analysis, Western Blotting analysis and 
identify gene expression changes by Microarray analysis. We also observed the 
potential morphological changes by microscopy. 
 
According to cell counts at each time point (day 1, 4, 7 and 14) growth curves were 
obtained. Control cells proliferated by approximately 8-fold in 14 days of the 
experiment, whereas the number of cells treated with 0.5 mM VPA has increased 
slightly in the first four days and remained stable for the duration of the experiment 













Figure 17: LCLs growth curves in 14 days long experiment. LCLs were counted at every time point (day 
1, 4, 7 and 14) and growth curves were obtained. Control cells increased in numbers, whereas number 
of cells treated with 0.5 mM VPA has increased slightly in the first four days but remained relatively 
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Furthermore, Western blotting analysis showed pronounced increase in acetylation of 
histones H3 and H4 after 0.5 mM VPA treatment at day 1. The acetylation remained 
high thereafter. In untreated control cells parallel increase in acetylation was 
observed, for reasons that are not clear (figure 18). 
 
 
Figure 18: Western blotting analysis of LCLs treated for 1, 4, 7 and 14 days with 0.5 mM VPA. Blots 
present changes in histone acetylation levels of control (C) and treated cells (0.5) in histones H4K5ac, 
H3K9ac, H4K16ac, H3K4me3 and H3 C-terminal upon 0.5 mM VPA treatment.  
 
Every second day photos were taken to observe potential morphological changes. In 
control groups, LCLs were growing in clumps and single cells were also observed. The 
treated cells in culture media with 0.5 mM VPA were growing as single cells with only a 
few clumps. After day 5 treated cells started to change morphologically from round 
shaped cells to spiky cells as presented in figure 19 below.    
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Figure 19: Example photos of LCLs in 14 days culture taken by light microscope.  LCLs were treated for 1, 4, 7 and 14 days with 0.5 mM VPA. Photos were taken at 
10x and 40x magnification and photos presented were taken from control groups and 0.5 mM VPA groups at days 1, 6, 8, 12 and 14. LCLs in control groups were 
growing in clumps with single cells however, treated LCLs were growing as single cells and clumps started to disappear with prolonged treatment. After 5 days of 
continuous treatment LCLs started to change shape from round to spiky. 
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To identify which genes change in LCLs upon VPA treatment we performed Microarray 
analysis and LCLs were collected as described in section 2.2.2. The cDNA from control 
and treated cells were hybridized to HX12 cDNA arrays. The intensities of probes 
hybridized with samples cDNA from control untreated and treated cells were 
compared (t-test). On the slide there were 44,049 human target gene sequences.  
 
We identified differentially regulated genes by T-Test and a fold-change cut-off of 2-
fold up or down in each time point. After one day of treatment only a small proportion 
of genes showed transcriptional change (202 genes, 169 up, 33 down), whereas after 4 
days of treatment the transcriptional change was more abundant (1224 genes, 452 up, 
772 down) with more genes being down regulated. After 7 days of treatment the 
number of genes with transcriptional change declined slightly (777 genes, 428 up, 348 
down). The maximal transcriptional gene change in up regulated genes was seen at 
day 14 (1013 genes, 922 up, 91 down). Data suggests that the number of up regulated 
gene increased through the duration of the treatment while the number of down 










Figure 20: Changes in transcriptional levels in LCLs. Cells were treated for 1, 4, 7 and 14 days with 0.5 
mM VPA and transcriptional responses were analysed with HX12 arrays. The number of genes that were 
more than 2-fold up regulated or down regulated at each time point are presented.    
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Interestingly, only 44 genes were significantly changed in all four time points (figure 
21). Genes from all four time points were analysed using DAVID bioinformatics 
software to perform gene ontology (GO). Enrichment analysis was performed for 
genes that exhibited above 2-fold change. The four most significantly enriched gene 
classes from each time point are presented in table 1 below. The highest fold 
enrichment was observed at day 7 with GO terms cell cycle, organell lumen, 



















Figure 21: Venn diagram showing changed genes in 14 day long experiment. LCLs were treated for 1, 4, 
7 and 14 days with 0.5 mM VPA. Genes transcription levels have changed significantly (P<0.01) upon 
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Table 1: LCLs gene ontology. DAVID bioinformatics software was used to perform gene ontology (GO) 
analysing genes from all four time points. Enrichment analysis was performed for genes that exhibited 




3.3. 24 hours exposure of BLs to different concentration of VPA  
 
To evaluate the effects of HDAC inhibitor VPA on malignant cells we as a cancer model 
used Burkitt lymphoma cell lines which are a B cell derived malignancy (Molyneux et 
al., 2012) and offer a valid comparison with our selected LCLs. In our experiments we 
used three BL cell lines (BL 30, 31 and 41) derived from primary BL tumours. These 
specific BLs were selected as being phenotypically very similar to each other and all 
negative for Epstein Barr Virus (EBV) thus removing any complications due to viral 
gene expression. BLs were treated with 0.2, 0.5, 1 and 5mM VPA for 24 hours to 
identify changes in cell cycle using FACS analysis.  
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When BL30 cells were treated with VPA there was a cell cycle arrest observed in G1 
and G2M phase of cell cycle without a significant increase in apoptosis. The trend was 
even more evident at 5mM VPA. In BL 31 and 41 cell lines substantial apoptosis was 
observed without significant cell cycle arrest (figure 22).  
 




Figure 22: Cell cycle changes in BLs after 24 hours treatment with VPA. BLs FACS analysis pictures 
present BLs cell cycle of control cells (C) and cells after treatment with 0.5, 1 and 5 mM VPA. In BL 30 
there was a cell cycle arrest in phases G1 and G2M without apoptosis. In BL 31 and 41 substantial 
apoptosis was observed without significant cell cycle arrest suggesting cells undergo apoptosis in all 
phases of cell cycle. 
 
3.4. BLs cell density vs. VPA treatment 
 
BLs 31 and 41 had a faster proliferation rate according to the observation of growth in 
culture in comparison to BL 30 cell line and this therefore raised the question whether 
BL 31 and 41 cell lines undergo apoptosis so significantly due to their faster 
proliferation rate and resultant overcrowding in culture resulting in higher apoptosis. 
Therefore, we designed an experiment to address the question, seeding all three BLs at 
different counts (1x106, 3x106 and 5x106 cells) and treating them with 0.5 and 5 mM 
VPA for 24 hours. The results were comparable to the results of the first BL experiment 
where BLs were treated with VPA described in section 3.3.  
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In BL 30 cell line cell cycle arrest was seen in G1 and G2M phase as loss of S phase of 
cell cycle but without significant apoptosis. In BL 31 and 41 cell lines there were no 
obvious cell cycle arrest but cells undergo apoptosis from all phases of cell cycle. 
Significant apoptosis was again seen when cells were treated with 5 mM VPA (figure 






















Figure 23: Cell cycle changes in BLs at different numbers of seeded cells. BLs were seeded at 1x106, 3x106 
and 5x106 cells and treated with 0.5 and 5 mM VPA for 24 hours. Example FACS pictures represent cell cycle profiles 
in control cells (C) and treated cells (5). Obtained profiles are comparable between different densities of seeded 
cells with the same concentration of VPA.   
 
3.5. BLs early responses to VPA treatment 
 
To elucidate early transcriptional responses of BLs to VPA treatment, a short-term 
experiment was conducted treating BLs in culture for 30, 60 and 120 min with 1 mM 
VPA. To address the question of how VPA affect levels of global histone acetylation in 
BLs Western Blotting analysis was performed. Furthermore, gene changes were 
identified by Microarray analysis.  
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Western Blotting analysis showed pronounced increase in acetylation levels of 
histones H3 and H4 in treated BL cell lines (BL 30, 31 and 41) with prolonged time. In 
untreated control BL cell lines (BL 30, 31 and 41) parallel increase in acetylation was 



















Figure 24: Western Blotting analysis of BLs. BLs (BL 30, 31 and 41) were treated for 30, 60 and 120 min 
with 1 mM VPA. Blots present acetylation levels of histones H3, H4 and H3 C-terminal tails in 
comparison to control untreated cells (C). With prolonged time acetylation levels are increasing seen as 
increased bulk in histones H3 and H4.  
 
 
To identify which genes change in BLs upon VPA treatment we performed Microarray 
analysis and BLs were collected as described in section 2.2.2. The cDNA from control 
untreated and treated cells were hybridized to HX12 cDNA arrays. The intensities of 
probes hybridized with samples cDNA from control untreated and treated cells were 
compared (t-test).  
 
On the slide there were 44,049 human target gene sequences and only 4091 (9.3%) in 
BL 30, 2044 (4.6%) in BL 31 and 1674 (3.8%) in BL 41 showed significant (P<0.01, 1.25-
fold) changes, in total from all time points, in response to VPA. From all significant 
genes there were comparable numbers of up- and down- regulated genes, as there 
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were 2321 up regulated and 1779 down regulated genes in BL 30, 1163 up regulated 
and 884 down regulated genes in BL 31 and 539 up regulated and 1135 down 
regulated genes in BL 41 at all three time points (30, 60 and 120 min). Interestingly, 
only a very small number of genes were significantly changed in all three time points 
within the same cell line. In BL 30 only 35 genes (4091 total) were significantly changed 
in all three time points, in BL 31 only 7 (2044 total) and in BL 41 only 3 (1674 total) 
(figure 25). 
 
 Genes from all three BLs from each time point were independently analysed using 
DAVID bioinformatics software to perform gene ontology (GO). Enrichment analysis 
was performed for genes that exhibited above 1.25-fold change. The four most 
enriched gene classes are presented in table 2 below. GO analysis revealed no 
significant enrichment in ontology terms in BL 31 at 60 min. Interestingly anti-
apoptosis, negative regulation of apoptosis and regulation of cell death were enriched 
in BL 30. In BL 31 the most interesting enriched GO terms were regulation of apoptosis 
and regulation of transcription and in BL 41 positive regulation of cell proliferation, 
negative regulation of protein kinase cascade and signal transduction.  
 
Figure 25: Venn diagram presenting numbers of significantly changed genes in BLs. Three cell lines of 
BLs were treated for 30, 60 and 120 min with 1 mM VPA. Genes transcription levels have changed 
significantly (P<0.01, 1.25-fold) upon VPA treatment detected by HX12 arrays (12 x 135,000 gene 
probes). 
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Table 2: Gene ontology for BL 30, 31 and 41.  DAVID bioinformatics software was used to perform gene 
ontology (GO) analysing genes from all BLs. Enrichment analysis was performed for genes that exhibited 
above 1.25-fold change. The four most significantly enriched gene classes are presented each cell line. 
GO results revealed no significant enrichment in genes for BL 31 at 60 min (fold enrichment below 2) 
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Additionally, we identified genes which showed changes in up regulation or down 
regulation by 1.25-fold in each time point. After 30 min of treatment only a small 
proportion of genes showed transcriptional changes (BL 30 - 258 genes, BL 31 - 144 
genes and BL 41 - 165 genes). After 120 min of treatment the transcriptional change 
was more abundant (BL 30 - 3150 genes, BL 31 - 1676 genes and BL 41 - 1379 genes). 
In BL 30 and 31 there were more genes up regulated, whereas in BL 41 there were 
more genes down regulated. The maximal transcriptional changes were observed at 





Figure 26: Changes in transcriptional levels in BLs. BLs were treated for 30, 60 and 120 min 1 mM VPA 
and transcriptional responses were analysed with HX12 arrays. The number of genes that were more 
than 1.25-fold up regulated or down regulated at each time point are presented.    
 
 
Moreover, we combined data obtained from each time point from all three BL cell 
lines and analysed the results. Between all three cell lines (BL 30, 31 and 41) there 
were no genes significantly changed in all three cell lines at 30 min and only 4 genes at 
60 min. Interestingly, there were 424 genes significantly changed at 120 min in all 
three BL cell lines (figure 27). These common genes at 120 min were significantly 
enriched for the ontology terms domain BTB (P=6.6E-4), zinc finger (P=2.3E-3), nucleus 
(P=6.8E-5) and regulation of transcription (P=2.6E-4). 
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Figure 27: Venn diagram presenting numbers of significantly changed genes at each time point. BL 30, 
31 and 41 data was combined and compared within time points. There were no significantly genes 
changed at 30 min and only 4 genes were significantly changed at 60 min. However, there were 424 
genes significantly changes at 120 min. 
 
Further analysis showed broadly similar number of significantly changed genes at 30 
min between BL 30, 31 and 41. However, at 60 min there were increased number of 
significantly changed genes in BL 30 in comparison to BL 31 and 41 and similar at 120 
min after treatment with VPA.   
 
 
Furthermore, we combined all data obtained from all three cell lines BL 30, 31 and 41 
and identified 444 genes (7809 total) being significantly changed in all three cell lines 
at 30, 60 and 120 min combined (figure 29). The common genes across all three BL cell 
lines were analysed using DAVID bioinformatics software to perform gene ontology 
(GO). Enrichment analysis was performed for genes that exhibited above 1.25-fold 
change. When comparing all 444 BLs common genes gene ontology terms appeared: 
Kelch (P=0.001), transcription (P=0.003), immune response (P=0.04), prostate cancer 
(P=0.02), small cell lung cancer (P=0.18), p53 signalling pathway (P=0.03) and apoptosis 
(P=0.01) (table 3).  
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Figure 28: Significantly changed genes in all BL cell lines in all time points. There were 444 genes (7809 
total) significantly changed in all three BL cell lines at 30, 60 and 120 min. 
 
 
Table 3: BLs gene ontology. DAVID bioinformatics software was used to perform gene ontology (GO) 
analysing genes from 444 BLs common genes across all three BLs. Enrichment analysis was performed 
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3.6. Gene comparison of LCLs to BL 30, 31 and 41 
 
To evaluate gene changes in response to VPA treatment in normal and cancer cells, 
short-term gene expression changes in LCLs, determined previously in our lab using the 
same expression array set up (Halsall, unpublished data) were compared to BLs. There 
were 942 common genes between LCLs and BL 30, 471 common genes between LCLs 
and BL 31 and 532 common genes between LCLs and BL 41. All common genes 
















Figure 29: LCLs vs. BLs gene comparison. LCLs were compared to BLs to evaluate gene changes. There 
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The aim of this thesis was to evaluate the effects of the HDAC inhibitor VPA on normal 
and cancer cells by identifying changes in cell cycles, global histone acetylation and 
changes in gene expression.  
 
Even with the increased knowledge of cancer hallmarks and advances in therapy 
regimes treatment of cancer is still challenging (Baskar et al., 2012). Conventional 
chemotherapeutics are usually toxic to normal cells which is hazardous to the patients, 
causing mild to severe side effects (Peedicayil, 2006). Therefore, even more advanced 
therapies need to be discovered and one of the promising therapies is the epigenetic 
therapy with HDACi (Mai and Altucci, 2009). HDACi have been used as anti-epileptics 
since anti-convulsant effects were observed in 1963 (Chateauvieux et al., 2010) and 
more recently are also used as anti-cancer therapy (Cortez and Jones, 2008). Before 
specific HDACi become available as chemotherapeutic agent benefits and side effects 
have to be studied and the effects on cancer and normal cells must be identified and 
compared.   
 
Results presented in this thesis showed that LCLs as well as BLs cell cycles were 
affected by VPA treatment. In LCLs there was no significant apoptosis observed 
whereas in two BL cell lines substantial apoptosis was observed. Furthermore, LCLs 
changed morphologically after day 5 of treatment, confirmed in two experiments 
where the onset was observed at the same day. Histone acetylation levels were 
increased in treatment groups of both cell types and GO showed enrichment of 
transcripts of genes involved in cell cycle and cell adhesion possible explaining 
regulation of cell cycle and changes in cell morphology in treated LCLs whereas, 
enrichment in apoptosis and regulation of transcription possible explaining substantial 
death and increase in acetylation levels in the treated BLs. Moreover, results showed 
that VPA selectively causes cell death of some BLs independent to cell density. These 
results showed a great potential of VPA to be used as chemotherapeutic agent as it 
induces cell death in cancer cells but not in normal cells and it works independent to 
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cell density suggesting that it could be used in treatment of solid tumours and 
hematopoietic cancers.  
 
The first two questions we addressed in this project was whether VPA treatment 
affects LCLs cell cycle, histone acetylation levels and cell morphology in 7 and 14 days 
of treatment alongside analysing gene expression of cells treated for 14 days. Our 
results obtained by flow cytometry from both experiments showed cell cycle arrest at 
the G1/S and G2M boundaries, which confirms observations of cell cycle arrest by 
Carew (Carew et al., 2008). Minimal apoptosis was observed when LCLs were treated 
with VPA (figure 14) which confirms Quintás-Cardama findings that HDACi do not 
induce apoptosis in normal cells (Quintás-Cardama et al., 2011). This suggests that VPA 
might be a cell cycle specific chemotherapeutic agent as it induces cell cycle blocks at 
two boundaries. The minimal apoptosis might suggest that cells undergo senescence 
due to the treatment but do not undergo apoptosis. From the LCLs growth curve it was 
clear that treated LCLs grow slower in comparison to the control untreated group 
(figure 17) what may be due to cell cycle blocks and therefore, fewer cells were cycling. 
In addition to these findings LCLs changed morphologically from round shape to spiky 
with prolonged treatment suggesting that this might be due to differentiation or 
hyperacetylation of actin fibres. It has been previously shown that VPA increases 
acetylation levels (Nightingale et al., 2007). Our results confirmed increase in histone 
acetylation levels in treated LCLs due to inhibition of HDACs. However, the increased in 
acetylation levels was observed in untreated control cells as well, for reasons that are 
not clear. Gene ontology (GO) results suggest that amongst genes whose expression 
changed after VPA treatment, the most enriched GO terms were related to cell cycle as 
this GO term appeared at day 4, 7 and 14. Also at day 4 we observed enrichment in GO 
terms for cell adhesion and cytoskeleton which may explain morphological changes 
and is consistent with the observed morphological changes after day 5. These changes 
may also be a consequence of hyper-acetylation of non-histone proteins by HDACi 
influencing on cytoskeletal molecules altering cell morphology.   
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LCLs survived in long-term experiment treated with 1 mM VPA. However, 24 hour 
experiment with BLs with different concentrations of VPA revealed BLs undergo 
apoptosis much faster than LCLs and therefore a long-term experiment was not 
conducted. Instead, a short term experiment was conducted.  
  
The next question to address was whether VPA treatment affects BLs cell cycle when 
treated for 24 hours. The obtained results presented this thesis showed clear evidence 
of cell cycle arrest at G1/S and G2M boundaries in BL 30 cell line with substantial 
apoptosis in BL 31 and 41 cell lines without clear cell cycle arrest suggesting that cells 
undergo apoptosis from all phases of cell cycle (figure 22). The results confirm findings 
from other research groups which show that HDACi induce cell cycle arrest (Carew et 
al., 2008, Shan et al., 2012). This might suggest that VPA is a cell cycle specific 
chemotherapeutic agent and that due to restoring of normal expression levels of 
tumour suppressor genes and potential activation of pro-apoptotic genes cells undergo 
substantial apoptosis. Both of these findings have been observed before when cancer 
cells were treated with HDACi (Bannister and Kouzarides, 2011, Quintás-Cardama et 
al., 2011).   
 
Furthermore, to confirm that substantial apoptosis in BLs is not due to high cell density 
of cells in culture. The experiment was conducted showing that cell density does not 
affects the VPA effects again observing cell cycle arrest at G1/S and G2M boundaries in 
BL 30 cell line and substantial apoptosis in BL 31 and 41 cell lines without clear cell 
cycle arrest independent of cell density (figure 23). This suggests that VPA would 
potentially still be cytotoxic to cancer cells in tumours with high density of cancer cells, 
at initial formation of tumours and in hematopoietic cancers.  
 
The last question to address in this project was whether VPA treatment affects BLs 
histone acetylation levels and gene expression levels when treated for 30, 60 and 120 
min. In BLs the increased hyperacetylation was even more evident than in LCLs as it 
has increased significantly with prolonged time (figure 24) confirming the results 
obtained from Halsall et al. and Yi et al. (Halsall et al., 2012, Yi et al., 2013). However, 
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in untreated control BL cell lines (BL 30, 31 and 41) parallel increase in acetylation was 
observed, for reasons that are not clear. 
 
GO results revealed differences when comparing enriched GO terms of LCLs and BLs in 
short-term experiments. In LCLs short-term experiment the earliest response was seen 
as enrichment in GO terms of LCLs at 30 min where terms related to regulation of 
apoptosis following by transcription and positive regulation of gene expression at 60 
min and transcription, zinc finger and Kelch genes at 120 min were enriched (data not 
shown) (Halsall, unpublished data). However, in BL 30, in which cell cycle response 
strongly resembled LCLs, enrichment in GO terms related to regulation of apoptosis 
and anti-apoptosis, suggesting that BL 30 cell line might be more resilient to VPA 
treatment. Moreover, BL 30 strongly relates to LCLs in transcriptional response as 
when comparing the responding genes results of BL 30 cell line and LCLs, BL 30 had the 
biggest proportion of common genes with LCLs compared to BL 31 and 41. Also, the 
increased number of changed genes in BL 30, in comparison to BL 31 and 41, suggests 
that BL 30 had stronger transcriptional response to VPA. In BL 31 and BL 41 cell lines 
GO terms including genes for transcription and regulation of transcription were 
enriched suggesting that transcription was increased which was already suggested by 
Marks and Xu (Marks and Xu, 2009). When GO analysis was performed for all three BL 
cell lines combined GO terms apoptosis, transcription and immune response were 
increased again confirming findings by other research groups. Furthermore, GO terms 
prostate cancer, small cell lung cancer and p53 signalling pathway were enriched 
suggesting that VPA might be affecting tumour signalling pathways what was already 
observed in treatment with HDACi (Quintás-Cardama et al., 2011). The combined GO 
results for all three BLs suggests that VPA affects malignant cells by tumour signalling 
pathways as this was not observed in LCLs.    
 
The limitations of this project could be the use of only one LCL cell line and a 
comparison to LCL cell lines from different donors would be welcome. Furthermore, 
this work was conducted as in-vitro experiments but experiments could be also 
conducted in-vivo.  
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However, the results presented in this thesis are very strong and convincing as results 
were obtained from data including three biological replicates which correlated well for 
each sample. Besides, all data was highly comparable between cell lines as all cell lines 
were B cell derived. Moreover, all our microarray slides were checked to have 
complete coverage.  
 
Additionally to circumventing the limitations of this project, results have to be 
confirmed. Therefore, gene primers should be designed and real-time PCR should be 
performed to confirm the expression changes seen by microarray. Furthermore, 
experiments to investigate whether LCLs are really differentiating due to the VPA 
treatment could be conducted. This may be done by examining differentiating cell 
marker expression changes etc. which should be investigated. Moreover, as cell cycle 
arrest was observed at two boundaries it would be interesting to investigate whether 
LCLs would enter a cell cycle again once VPA treatment would finish. As some studies 
suggested that HDACi effects on correcting epigenetic defects could be reversible after 
the end of treatment (Peedicayil, 2006) this could be further investigated in BLs 
experiment with longer treatment period with subsequent withdrawal of VPA to assess 
acetylation levels and changes in gene expression levels. As cell cycle specific 
chemotherapeutic agents usually only work on cycling cells it would be interesting to 
investigate what would happen if cancer cells would achieve a plateau phase prior to 
VPA treatment as this is sometimes seen in solid tumours when discovered in a late 
stages. Would VPA still induce as high apoptosis as seen in this project? To obtain gene 
networks affected by VPA further data analysis is of high importance to obtain targets 
affected by VPA. Also, further experiments could be conducted using other types of 
cancers, e.g. T cell derived cancers which could be compared to T cell clones as a 
model for normal human cells. Furthermore, these results could be compared to 
results from SAHA treatment to assess the mean of action of different HDACi as SAHA 
is already used for treatment of T cell malignancies.         
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Results of this thesis showed that both LCLs and BLs experience a cell cycle arrest with 
cell death observed in BLs which was independent of cell density. LCLs also showed 
changes in cell morphology in response to VPA treatment. In all VPA treated cells 
histone acetylation levels were increased. One of the most important findings of this 
project was that normal cells do not undergo apoptosis when treated with VPA and are 
therefore more resilient to VPA, whereas some cancer cells do. This suggests that VPA 
is not as toxic to normal cells as other chemotherapeutic agents and this may lead to 
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